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Abstract 
Platinum-based drugs play a very important role in the cancer chemotherapy. This 
thesis focuses on the development of Quantitative Structure Activity Relationship(s) 
(QSAR) of platinum drugs as means of contributing to the design of platinum drugs. 
In order to obtain a useful and universal QSAR, all searchable and named platinum 
drugs with biological data available in the National Cancer Institute (NCI) database 
were selected for the QSAR study. 
Chemical Hardness, a Density Functional Theory (DFT) reactivity index, was used to 
construct the overall QSAR of platinum drugs. Satisfactory correlations between 
chemical hardness and potency (Log GI50) of platinum drugs were found. It 
demonstrates that potency of the drugs increases as the chemical reactivity increases. 
The QSAR results show that chemical hardness could be a practical and universal 
parameter in predicating the potency of platinum drugs. This may provide a useful 
reference for future in platinum drug design work. 
A QSAR study on twelve drugs with two chlorides as leaving ligands (Pt-Cl) was 
independently performed. The reason for selecting these drugs is that they belong to 
same structure analogue and have the same leaving ligand as Cisplatin, the most 
widely used platinum drug clinically, and that this series provides enough data points 
for a meaningful QSAR study. The Chemical hardness of their possible intermediates 
in biological system was calculated. The results confirmed that drug potency 
depended more significantly on the chemical hardness of parent compounds. 
Due to the fact that potency of Pt-Cl drugs depended primarily on the chemical 
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hardness, hence the chemical reactivity of their parent compounds, the reaction energy 
profiles of the first reaction step of the three possible DNA binding pathways were 
investigated; the direct guanine binding, hydrolysis pathway and methionine pathway 
were investigated. QSAR analysis was performed using AG+(hydrolysis)， 
AG(hydrolysis), AG+(guanine) and AG(guanine). We found that the parameter 
AG+(guanine) shows a noticeable correlation with potency of the drugs, which 
suggested direct guanine binding may exists in complicate cell environment. The 
strongest correlation was found in the QSAR plot of potency against AG(guanine)，it 
suggests that as the DNA binding affinity of platinum drugs increase, the potency 
increases. This finding provides one more useful parameter for designing new 
compounds besides the chemical hardness. The applicability of the parameters 
AG+(guanine) and AG(guanine) were tested against platinum drugs with bidentate 
carboxylate leaving ligands, which is another important type of platinum drugs 
besides cisplatin analogue. Carboplatin and the five Pt-DMC compounds designed 
and synthesized by this group were selected for the study, and observations similar to 
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Introduction And Background 
1.1 Introduction of Platinum Drugs 
Platinum based antitumor drugs have been widely utilized since 1960s when 
Rosenberg accidentally discovered the inhibition of cell division by platinum 
complexes.[1.1] Cisplatin (cis-diammine-dichloro-platinum(II), figure 1.1.1) that is 
the platinum compound for the phenomenon becomes one of the most extensively 
used antitumor drugs in the world. [1.2] 
• 3 、 . C I 
NH3Z CI 
Figure 1.1.1 Cisplatin 
Cisplatin contributes significantly in curing various types of cancer. It cures 70-90% 
of cases of testicular cancer, even when the cancer has spread beyond the testes. [1.2] 
And it is also highly effective in curing ovarian cancer and contributes in the 
treatment of bladder, cervical, head and neck, esophageal, and small cell lung 
cancer. [1.2, 1.3] 
However, several disadvantages associated with cisplatin. They include the severe 
toxicity such as nephrotoxicity, neurotoxicity and emetogensis [1.4], drug resistance, 
limited aqueous solubility and restriction to intravenous administration. [1.5] These 
limit the practical usage of cisplatin and led to the strong demand in development of 
new platinum based drug. 
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To find a superior drug obviously is a difficult task. In the past 30 years, thousands of 
platinum compounds have been synthesized and only about 28 of them have entered 
clinical trials. [1.4，1.5] Besides cisplatin, only three platinum drugs are registered as 
market drugs. They are carboplatin, oxaliplatin (registered for use in Europe) and 
nedaplatin (registered for use in Japan)[1.3] (Figure 1.1.2). 
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Figure 1.1.2 Other Registered Platinum Drugs 
Comparing to cisplatin, the toxicity of carboplatin is milder and has the better 
tolerability in general. However this drug serves the dose-limiting factor of 
myleosuppression which is not severe with cisplatin. [1.6] And carboplatin shares 
similar spectrum of activity with cisplatin, this limits carboplatin to become a superior 
drug comparing with cisplatin. 
For oxaliplatin, except its significant neurotoxicity, the toxicity profile of oxaliplatin 
is generally lower than that of cisplatin,[1.7] also this drug has a different profile of 
activity and low cross-resistance with cisplatin. This suggests that oxaliplatin may 
have different mechanism or target of action from cisplatin. [1.8] 
Nedaplatin has been registered for use in Japan. This drug shows similar spectrum of 
activity with cisplatin. [1.9] Phase I clinical study suggests that this compound has 
markedly lower nephrotoxicity, digestive toxicity, neurotoxicity, and acoustic toxicity 
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than cisplatin. However, similar to carboplatin, this drug serves the dose-limiting 
toxicity of bone marrow suppression related to leukopenia and thrombocytopenia. 
[1.10] 
And for the details of other platinum drugs development, reader can refer to the 
review papers and books. [1.4 -1.6 , 1.11 - 1.16] 
1.2 Mechanism of Action of Cisplatin 
It is generally accepted that binding of cisplatin to the genomic DNA contributes 
mainly to the antitumor effect of the drug. The damage induced by cisplatin may 
interfere with normal transcription and DNA replication mechanisms and finally leads 
to the death of the cancer cell. [1.3] It was shown that cisplatin would preferentially 
react with the N7 position of the imidazole ring of guanine (G) or adenine (A), 
forming different monofunctional or more importantly, bifunctional adducts. 
(Figure 1.2.1) 
J \ 
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Figure 1.2.1: Schematic Diagram for D N A Binding of Cisplatin and the Resulting Distortion of D N A 
The major DNA adducts formed by cisplatin can be identified by the enzymatic 
digestion of the cisplatin-treated salmon sperm DNA followed by chromatographic 
separation of the products and NMR analysis. [1.13] The major product was 
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1,2-intrastrand cross-links with two adjacent guanine bases, c/5-[Pt(NH3)2{d(GpG)}] 
(cz^-GG) (47-50%) and the second major adduct was 1,2-intrastrand cross-links with 
adjacent adenine and guanine bases, cz5-[Pt(NH3)2{d(ApG)}] (cw-AG) (23-28%). 
Moreover, there were 8-10% 1,3-intrastrand cross-links with non-adjacent guanines 
(c/5-GNG) and interstrand adducts, also 2-3 % of product was monofunctional 
adducts binding to guanine.[1.13] 
Another similar study using the compound [Pt(en)Cl2] that was expected to have 
similar binding properties with cisplatin also showed that (cis-GG) was the major 
product. (65% cis-GG, 25%, cis-AG and 6% as-GNG). [1.13] 
1.3 Structure-Activity Relationships of the Platinum Drug 
One of the scopes of this thesis is to establish the quantitative structure-activity 
relationship (QSAR) of the platinum drugs through some simple parameters. The 
science of the quantitative structure-activity relationships (QSARs), at the interface 
between chemistry and biology plays an important role in modem drug design. [1.17] 
QSAR attempts to find the consistent relationships between molecular properties and 
biological activities for a series of compounds so that these "rules" can be used to 
evaluate new chemical entitles [1.18] 
Actually there are only few publications concerning the QSAR of the platinum drugs. 
The following are the brief reviews for QSAR of platinum drugs: 
The majority of the earlier publications used the structural descriptors such as 
electronic properties, hydrophobicity and the steric effects for QSAR studies of the 
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platinum drugs. Abdul-Ahad and Webb [1.19] studied the relationships between 
standard biological activity indicators, including, acute toxicity (pLDso), antitumour 
potency (pIDgo) and the therapeutic index (log TI) and a variety of structural 
descriptors. These structural descriptors consisted of a wide range of electronic 
parameters, and one steric parameter [molecular volume (MV)]. Moderate to strong 
correlations with a high degree of statistical significance were obtained in some cases. 
However, using MV as the steric parameter oversimplified the case and also 
parameters concerning transport phenomena such as hydrophobicity were not 
included in the study. [1.20] 
Tang et al. [1.21] used exclusively electronic descriptors by the CND0/2-SCF method 
to study the QSAR of about 40 platinum complexes whose activities against ADJ/PC6 
and S-180 in mice were well known. The parameters used in the study included the 
partial charges on the platinum, carrier and leaving ligand of the complexes, the 
overlap population of Pt-Cl and Pt-N bonds, AE (AE = energy difference between 
LUMO and HOMO), AQ (AQ =Qpt-ci 一 Q pt-N) and number of protons on N atoms of 
amine. Furthermore, these authors reported the synthesis of a complex designed with 
the electronic characteristics required by their regression results and this complex 
showed the desired properties with high potency and low toxicity. However, the 
generality of this approach was not certain, also, many descriptors were interrelated 
and same information may be carried by more than one parameter. This may lead to a 
false conclusion due to the co-linearity. 
Simon et al [1.22, 1.23] who employed both the hydrophobicity, electronic and steric 
parameters suggested that the therapeutic index (TI) depended significantly on the 
steric effect. However, considerable criticism was received for his approach of 
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receptor mapping procedure for the steric optimization. [1.24，1.25] 
Orbell et al [1.20] used the repulsive energy strategy in an attempt to delineate the 
steric contribution to the biological activity of variety of platinum-am(m)ine 
complexes. Results showed that the parameters for the repulsive energy strategy in 
that study did not reveal any obvious correlation to the biological activity. 
Besides measured physicochemical properties and computed descriptors representing 
classical QSAR studies, Romanowska and co-workers [1.26, 1.27] showed the 
usefulness of molecular topology for QSAR study. Using graph-theoretical 
descriptions for obtaining the topological feature, the correlations between topological 
features of molecular structure and the biological properties were examined. Recent 
publication from Osella et al and co-workers [1.28] also used the theoretical 
molecular descriptors to encode the topology and geometry of the thirteen 
diamine-platinum(II) complexes. 197 out of 626 molecular descriptors were used for 
the QSAR analysis of the A2780 human ovarian cancer cells and cisplatin-resistant 
counterparts A2780Cp8. The search for the best regression models was carried out 
using an exhaustive algorithm that examined all the possible descriptors combinations 
with dimensionality from 1 to 4. By the cross-validation procedure, the best 
correlations were selected for each dimension, and finally, by the comparison of the 
statistical information of each dimension, a reference QSAR model was selected for 
each response [log(l/IC5o) of A2780 and A2780Cp8 and the resistance index (RI) of 
them]. The results of the progression were interpreted by the principal component 
analysis. And it was found that the biological profile of the studied platinum drugs 
depended mostly on the electronic properties descriptors. 
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Although, topological indices or theoretical molecular descriptors can generally offer 
an almost universal mean of representing a chemical structure, they usually lack a 
clear physical and chemical meaning and are unable to be extrapolated to other type 
of compounds. [1.29，1.30] 
Cundari et al. [1.31] used the combined methods of Monte Carlo (MC), molecular 
dynamics (MD) and molecular mechanics (MM) to search for the ensemble of 
low-energy conformations (LECs) for eleven c/«s-PtCl2(NH2R)2 with different 
flexibilities. After obtaining the ensemble of LECs, the minimum, maximum and 
average volume and surface area for all LECs were collected. They found that the 
average surface area and volume had a strong correlation (R=0.99). Moreover, 
reasonable linear correlation (R=0.83) between the pLDso and average volume was 
found which suggested the larger the volume, the lower the toxicity. However, there 
was no clear relationships between the biological parameters, pID90 and p(TI) and the 
structural parameters, surface area or volume. 
Besides standard indicators of biological activities (e.g. ID, LD and TI), QSAR study 
of the mutagenicity of the platinum drugs was also the concerns of researchers. Hanch 
and collaborators [1.32] proposed a QSAR model correlating mutagenicity in the 
Ames test with the Hammett electronic parameters for a series of 4- and 
4,5-substituted dichloro-1,2-(phenylenediamine) platinum(II) compounds. Recently, 
Costa and Santos [1.33] first reported the QSAR analysis of a set of 4-substituted 
(o-phenylenediamine) platinum(II) dichloride derivatives using rate constants of the 
first step of hydrolysis calculated by the quantum mechanism methods. Hartree-Fock 
(HF) and second-order Moller-Plesset perturbation theory (MP2) methods were 
employed. The correlations between the mutagenicity described in the paper by 
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log(l/C) and the ratio of hydrolysis rate constant log(kx/kh) (kx and kh denote the 
hydrolysis rate constant of the compound with X and H substituted at 4-position of the 
o-phenylenediamine respectively) were obtained. And the results showed that the 
analogues containing substituents that lead to a faster hydrolysis inducing less 
mutagenicity. 
From the above literatures, it can be seen that most of the QSAR publications focused 
on a relatively small set of platinum drugs or they confined their analysis in a similar 
type of platinum drugs. Moreover, the biologically data used for their QSAR studies 
was obtained from one or just a few types of cell lines. They did not provide an 
overview of structure-activity relationships of the platinum drugs. Therefore, one of 
the scopes of this project is to establish an overall picture of the QSAR of platinum 
drugs. Al l searchable and named platinum drugs with biological data available in 
the National Cancer Institute (NCI) database are chosen for the QSAR analysis. In 
order to provide an overall insight in the response of cancer cells to the drugs, the 
average value of logGIso (GI50： dose concentration inhibition 50% of cell growth) 
from 60 human cell lines screening is used as the biological parameter for the QSAR 
study. 
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1.4 QSAR Parameters 
In this QSAR study, chemical reactivity of the platinum drugs is focused. DFT 
computational methods are used for obtaining the reactivity parameters. The project 
wil l be divided into to two parts. The first part of the project focuses on the term 
chemical hardness (rj) which is one of the global reactivity index provided by DFT. 
Then in the second part of the project, energy profile parameters including free energy 
change and activation energy of the possible reaction of platinum drugs in biological 
system wil l be employed in our QSAR analysis. 
1.4.1 Chemical Hardness: Descriptor of Chemical Reactivity 
Chemical hardness (rj), is not a new concept in chemistry. With DFT, chemical 
hardness is provided with the useful universal definition for operation which plays a 
significant role in the study of molecular properties. 
DFT focuses on the electron density, p(r), itself as the carrier of all information in the 
molecular (or atomic) ground state, and the chemical reactivity is reflected by its 
sensitivity to perturbations. [1.34] 
The definition of the chemical hardness in DFT is as follows: 
斗 = 斗 g ] (1.4.1.1) 
f 
— (1.4.1.2) 
彿人 ( r ) 
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where v{r) is the potential due to the fixed nuclei 
Chemical Hardness (17) is the second derivative of E (energy) with respect to N 
(number of electrons), while the electronic chemical potential is the first derivative of 
this energy function (Figure 1.4.1.1). The absolute definition of chemical hardness 
was given by Parr and Pearson et al in 1983. [1.35] It measures the resistance to 
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Figure 1.4.1.1 Total Electronic Energy as a Function of Number of Electrons 
Adapted from: Parr, R. G; Pearson, R. G J. Am. Chem. Soc., 1983，J05, 7512. 
By applying finite difference approximation described above, it can be realized that 
the mean slope for the change from (N-1) to N electrons is the negative of ionization 
energy, I and the mean slope from N to (N+1) electrons is electron affinity, EA. 
Therefore, the operation definition of chemical potential and hence chemical hardness 
can be obtained: 
f I + EA^ /I 1 a � 
^ - ( 1 . 4 . 1 . 3 ) 
V 2 y 
f l - E A ^ , 1 … � 
r}= — — (1.4.1.4) 
\ ^ J 
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According to the Koopman's theorem, the ionization potential is the negative of the 
orbital energy of the HOMO (fHOMo) and similarly the electron affinity is the negative 
of the orbital energy of the LUMO (6LUMO)- Thus, chemical hardness can be written 
as[1.36]: 
” 〔 一 (1.4.1.5) 
I f the usual diagram of the MOs of a molecule as a function of their energy is drawn, 
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Figure 1.4.1.2 Orbital Energy Diagram for a Molecule 
Adapted from: Pearson, R. G. Chemical Hardness Application From Molecules to Solids, 
Wiley-VCH, 1997; p. 39. 
Here a clear relationship between chemical hardness and chemical reactivity can be 
obtained. By the quantum mechanical theory of response to a perturbation, during the 
11 
chemical reaction, changes in electron density occur by mixing excited-state wave 
functions with ground-state wave function. The mixing coefficient is inversely 
proportional to the energy difference between the states. Therefore, the soft molecules 
which have the smaller energy gap between ground state and excited state would have 
the higher tendency of mixing, hence with higher reactivity. [1.36] Thus, with the 
physical significance of chemical hardness provided, chemical hardness are employed 
in this work as a meaningful reactivity parameter to establish the overall QSAR for 
platinum drugs. 
1.4.2 Possible Reaction Pathway of Platinum Drugs 
After providing an overall QSAR picture of platinum drugs using chemical hardness, 
we further focus on the study of platinum drugs with dichloride as the leaving ligands 
(Pt-Cl). The reason to study the Pt-Cl drugs is that they are analogous to the most 
important platinum drug, cisplatin, with chloride as the leaving ligands and they are 
the most typical type of platinum drugs so far developed. Also, twelve Pt-Cl drugs are 
found in the NCI database, this offer enough data points for a complete and 
meaningful QSAR study. By the results of the study, chemical hardness data shows 
that potency of the Pt-Cl drugs depends on the chemical reactivity of their parent 
compounds instead of their possible biological intermediates. In order to study the 
actual chemical reactivity of the Pt-Cl drugs in biological system and construct a 
QSAR with a stronger physical significance, the energy profile of first step reaction of 
the three possible DNA binding pathways namely, hydrolysis pathway, methionine 
pathway and direct guanine binding pathway wil l be studied in detail. 
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1.4.2.1 Proposed DNA Binding Pathway of Platinum Drugs 
/ Cell Cytoplasm \ 
/ Pt-S-Bio-molecuIe 广 \ 
X C e l l N u c l e u ^ \ 
V Pt-H2o/ J 
Figure 1.4.2.1.1 Schematic Diagram for the Two Proposed DNA Binding Pathways for Platinum Drugs 
There are two proposed mechanisms for the DNA binding of platinum drugs. One is 
hydrolysis pathway in which the Pt drugs would first undergo hydrolysis to form the 
active aquated species and then bind to the DNA. Another pathway (methionine 
pathway) involves the preliminary binding of platinum drugs to sulfur-containing 
biomolecules, followed by migration of the Pt-centre to the guanine of DNA. (Figure 
1.4.2.1.1) 
1.4.2.1.1 Hydrolysis Pathway 
Hydrolysis pathway is the earliest proposed mechanism for the DNA binding of 
platinum drugs. There are plenty of publications concerning the hydrolysis pathway of 
cisplatin. Among them, the '^^Pt NMR study by Lippard el al [1.37] and the 
NMR study by Sadler el al [1.38] clearly illustrated the details of the hydrolysis 
pathway. The advantage of using the NMR spectroscopy is that it can identify and 
monitor the evolution of the species in the reaction system in-situ and simultaneously 
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without introducing any disturbance to the system. 
Lippard el al demonstrated the hydrolysis pathway using the reaction between 
cisplatin and chicken erythrocyte DNA. Stepwise mechanism for the binding of 
cisplatin to DNA was proposed (Figure 1.4.2.1.1.1): 
c H P t ( N H 3 ) 2 C l 2 ] ^ ^ c H P t _ 3 ) 2 ( H 2 0 ) C l ] + ——-cw-[Pt(NH3)2Cl(N7-pGp)]-' 
czHPt_3)2(H20)(N7-pGp)]2+ ——^ czWPt_3)2(N7-pGp)2]2+ 
Figure 1.4.2.1.1.1 Hydrolysis Pathway for Cisplatin Porposed by Lippard et al. 
From their experiment, no NMR peak due to the formation of c/^y-[Pt(NH3)2(H20)Cl]+ 
and d>y-[Pt(NH3)2(H20)2]2+ were observed. Their explanation was that the half-life of 
the two species were short (within minutes), hence the steady-state concentrations of 
the two species were too low to be observed during the reaction. The evidence for the 
hydrolysis pathway can be revealed from the fact that the rate constant of initial 
binding of DNA (10.2 x 10'^  s"') was similar to the rate constant of first hydrolysis 
(9.5 X 10-5 s-i) In addition, the pseudo-first order rate constants for the disappearance 
of cisplatin in the presence of DNA were the same for different initial concentrations 
of DNA. Concerning the ring closure of monofunctional adduct 
d«s-[Pt(NH3)2Cl(N7-pGp)]+ to bifunctional adduct m-[Pt(NH3)2(N7-pGp)2:r，the rate 
constant measured was 9.2 x 10'^  s''. It was similar to the rate constants obtained from 
the second hydrolysis of platinum complexes (4.2 x 10"^  s'' to 8.1 x 10"^  s"'). This 
suggested that the ring closure step was via the preliminary rate determining 
hydrolysis step of monofunctional adducts rather than the direct displacement of 
chloride by a second nucleotide on DNA. 
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Sadler et al. studied the similar reaction of cisplatin with GG single and double 
stranded decanucleotides. With the NMR spectroscopy, aqua-chloro 
intermediate (d>y-[Pt(NH3)2(H20)Cl]+)，was observed with reported half life of 8 min. 
This was close to the value of 6 min estimated by Lippard et al. Moreover, both the 
initial attack of DNA by cisplatin and the rate of ring closure appeared to be rate 
determined by corresponding hydrolysis steps. This further supported the hydrolysis 
mechanism suggested by Lippard et al. 
Sadler et al. [1.39] also studied the reactions of carboplatin with water and 5，-GMR 
By the NMR, reaction of carboplatin with water at 310 K and pH 7 was studied. 
Results after 2 weeks incubation showed only the peaks for the intact carboplatin and 
no free cyclobutane-1,1 -dicarboxylate (CBDCA) was detected. This indicated that 
carboplatin is inert to hydrolysis which is different from that of cisplatin. And from 
the results of the reaction with 5'-GMP, intermediate 
m-[Pt(NH3)2(CBDCA-0)(5'-GMP)] together with the product 
c/«s-[Pt(NH3)2(5’-GMP)2]2+were observed, also the presence of chloride did not alter 
the rate constant for either step of the reaction with 5'-GMP. This suggested that 
direct attack of nucleotides on carboplatin may be the important mechanism for the 
drug. Kinetics analysis revealed that the second step of the reaction of the bis 
5'-GMP adduct, d«KPt(NH3)2(5，-GMP)2]2+, formation (3.3 x 10'^  s」）was seven times 
faster than the first attack of 5'-GMP (4.1 x 10"^  s"'). Therefore, the rate determining 
step for the DNA binding appeared to be the first step of 5'-GMP direct attack. 
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1.4.2.1.2 DNA Binding Pathway Involving the S-containing Biomolecules 
(Methionine Pathway) 
Besides DNA, sulfur-containing bio-molecules such as methionine, cystein and 
glutathione may also play an important role for the antitumor activity of the platinum 
drugs. The identification of methionine-containing metabolites in the urine of patients 
receiving cisplatin therapy and the rapidly formation of Pt (Il)-methionine complexes 
in plasma after injection of cisplatin into rats [1.40] demonstrated the above point of 
view. 
For the DNA binding pathway, many evidences showed the possibility of 
sulfur-containing biomolecules being the intermediate binding sites for the Pt 
complexes before the drugs reaching the DNA. The concept of Pt-sulfur interactions 
serving as a "drug reservoir" for plantation of DNA has been suggested, thus 
affording an additional pathway toward platination of DNA [1.41]. Literatures 
demonstrated the viability of the "drug reservoir" idea by the systems with 
intramolecular and intermolecular competition between S-donor ligands, such as 
cystein, methionine and the nitrogen donors, such as guanine and adenine. 
Lempers et al studied the intramolecular competition using model SAH 
(S-adenosyl-L-homocysteine) and SGH (S-guanosyl-L-homocystein): 
O 
NH2 [ 
/ r ^ N f i T r 
V l A ^ ccv h ^ h 




In order to prevent the complication by the loss of NH3 ligand in cisplatin due to the 






Results in study using SAH showed no coordination, neither to the adenine N1 nor to 
the N7 atom. Instead, a pH-dependent migration of the platinum atom from the sulfur 
atom to the amine group of the cystein moiety was observed and vice versa. [1.42] On 
the other hand, encouraging results from the model SGH were obtained. Upon the 
reaction of SGH with 1 equiv of [Pt(dien)Cl]Cl at 2 < pH < 6.5. The species 
[Pt(dien)(SGH-5)]2+ formed rapidly in the initial stage of reaction. Then, it was 
observed that this species slowly isomerized into [Pt(dien)(SGH-A/7)]2+ with 
coordination at N7 of guanine. [1.43] It was the first time showing the phenomenon 
that N7 donor atom can replace the sulfur atom in a platinum-sulfur adduct. 
In order to study the "drug reservoir" idea at higher pH, free amino group had to be 
avoided, model species Met-d(TpG)' and Met-d(TpGpG)^" therefore were designed: 
o 
O H H s C y ^ N 
H 。 1 I C。2-° f ^ 0 
0X0- < / T r h O h O 
h ^ h •=?-。- ( / J 1 
OH H N ' ^ N H , 
OH H _ 
Met-d(TpG)" Met-d(TpGpG)2-
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In addition to [Pt(dien)Cl]Cl，bifunctional compound Pt(en)Cl2 was also employed: 
L 乃 、NH2 CI 
Pt(en)Cl2 
In the reaction of [Pt(dien)Cl]Cl with Met-d(TpG)", the formation of complex 
[Pt(dien){Met-d(TpG)}-习 + was observed to be completed within 2 hr. This 
S-coordinated species then underwent slow isomerization to form the NT-coordinated 
complexes [Pt(dien){Met-d(TpG)}-N7]+，and no S-coordinated species was found 
after the 6 days incubation. When bifunctional complex Pt(en)Cl2 was used, 
coordination of sulfur was completed within 10 hr which was slower than 
[Pt(dien)Cl]Cl. It was then followed by the fast chelation step to yield the stable 
macrochelate [Pt(en){Met-d(TpG)}-A7,5]+. [1.44] 
The further investigation involved the reaction of [Pt(dien)Cl]Cl and Met-d(TpGpG)^'. 
Similar to previous results, initial sulfur coordination was observed followed by the 
displacement with NT's of both guanines to form the 
[Pt(dien){Met-d(TpGpG)}-N7(5'G)] and [Pt(dien){Met-d(TpGpG)}-N7(3'G)]. [1.45] 
Apart from the intramolecular models, the concept of "drug reservoir" was 
investigated by the more "in vivo like" intermolecular competition models. 
Sadler et al first studied competition reactions between [Pt(dien)Cl]Cl, methionine 
and 5'-GMP by ^H NMR. In the first 40 hr, reaction of [Pt(dien)Cl]Cl with 
methionine occurred with little amount of 5'-GMP being reacted (140 x lO""^  at 
300K ). Then in the later stage of the experiment, displacement of methionine by 
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5'-GMP was observed with the free methionine being released (1.66 x lO'^^M'^s'^ at 
31 OK). In the related study, adenosine 5'-monophosphate (5'-AMP), thymine 
5'-monophosphate (5'-TMP), cytosine 5'-monophosphate (5'-CMP) and histidine 
were used for the displacement experiment with the complex [Pt(dien)(Met-5)]2+. 
However, in either case, no reaction was observed within 12.6 hr. [1.46] 
A similar study was reported about the plantation of 5'-GMP by the Pt-S adduct 
[Pt(dien)(GSMe-5)]2+，Reedijk et al, employed the S-methyl glutathione (GSMe): 
O 0 f 3 o 
NH3 H o 
GSMe 
'From their results, the intermolecular displacement of the thioether was also observed. 
Similar to previous results, this displacement was occurred only for guanine, but not 
adenine. In addition, no similar displacement by 5'-GMP was detected when the 
reaction was performed by glutathione (GSH) instead of GSMe [1.47]. 
/ S - H 
o o 「 H o 
NH3 o 
GSH 
The above publications demonstrated the role of the sulfur-containing biomolecules in 
the DNA platination mechanism with the suggested "drug reservoir" concept. 
Further study for tracing the displacement reaction species was performed by Sadler 
et al [1.48] The complexes [Pt(en)(MeC0-Met-<S)Cl]N03 (MeCO-Met = 
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A^-acetyl-L-methionine) was allowed to react with the 5'-GMP and dGpG. The 
reaction was monitored by the ^H and 2D [^H/^N] NMR at 31 OK. In the initial stage 
of the reaction, the intermediate chelate complexes were observed with the 
[Pt(en) {MeC0-Met-5',A^ ] being the major species and [Pt(en) {MeCO-Met-5,0}] 
being the minor species. It was believed that hydrolysis was occurred before the 
chelating of the 7V-acteyl-L-methionine ring although no peak for the aqua species 
[Pt(en) {MetCO-Met-S} ( H 2 O ) ] was observed. The absence of the peak was due to the 
short-live nature of the aqua species with the rapid ring closure to give 
[Pt(en) {MeCO-Met-5,A^ ] and [Pt(en) {MeCO-Met-5,0} ]. The two intermediate 
chelate complexes then reacted with 5'-GMP or dGpG through a ring opening step, 
yielding the monofunctional [Pt(en){MeCO-Met-5}(5，-GMP-7V7)]+ and 
[Pt(en){MeCO-Met-AS} {dGpG-7V7}]+ respectively. Slow displacement reaction of 
A^-acteyl-L-methionine by 5，-GMP or dGpG was then observed to afford the final 
bis-GG adducts. Figure 1.4.2.1.2.1 shows the proposed reaction scheme for the 
reaction of [Pt(en)(MeC0-Met-5)Cl]N03 with 5’-GMP and dGpG 
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Figure 1.4.2.1.2.1 Reaction Scheme for the [Pt(en)(MeC0-Met-5)Cl]N03 with 5’-GMP and GpG 
1.4.2.1.3 Conclusion 
As stated in the above literatures, both hydrolysis and binding pathway involving 
S-containing biomolecules may play the significant role in Pt-DNA binding. Detailed 
study in the kinetics and thermodynamics aspects of the first step of the two proposed 
DNA binding pathways provides valuable information on the actual chemical 
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reactivity of the parent platinum drugs in the biological system. While the third 
possible binding pathway, direct DNA binding, although it is not believed as the 
dominate DNA binding pathway for cisplatin and the similar analogue, its possibility, 
especially in the complicate cell environment, cannot be ruled out. Therefore, the 
three possible DNA binding pathways wil l be included in the DFT reaction 
calculation. 
In order to manage the computational resources effectively, simple guanine and 
methionine molecules are employed as the model to represent large DNA and 
S-containing biomolecules respectively. Thus, they are named as "direct guanine 
binding" and "methionine" pathway throughout the study. 
1.5 Thesis Scope 
As there is no QSAR concerning the overall picture of the platinum drugs so far, one 
of the main objectives of this project is to establish a practical overall QSAR of the 
platinum drugs. In order to include a representative variety of platinum drugs, all the 
searchable and named platinum drugs with biological activity available in the NCI 
database are included in the construction of the universal QSAR. The practical QSAR 
and hence the drugs potency prediction are explored by the meaningful DFT reactivity 
parameter, chemical hardness. 
Moreover, by the advanced studies of the chemical reactivity of the parent platinum 
drugs and their important biological intermediates, focus on the investigation of the 
detail chemical reactivity of the parent drugs becomes clear. Hence, another effort of 
the project is put on the thermodynamics and kinetics study of the first reaction step 
of the introduced three possible DNA binding pathways. Platinum drugs with 
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dichloride as the leaving ligands are selected in this part of research. Finally, the 
applicability of the established QSAR in this part is verified by another important type 
of platinum drugs with carboxylate bidentate leaving ligands. 
Therefore, the overall aim of this project is to figure out the importance of the 
chemical reactivity in the overall potency of the platinum drugs, both by the DFT 
reactivity parameter and the actual reaction energy profile. Then, by the established 
correlations between potency and chemical reactivity, practical correlation equations 
are provided for researchers as a reference to predict the potency of the drugs without 
actual synthetic works. 
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Chapter Two 
Theory And Methodology 
2.1 Introduction 
In this chapter, general theoretical background of the work wi l l be provided. First, 
basic idea of Density Functional Theory (DFT) is described and it is followed by the 
brief introduction of the Basic Sets and Solvation Models. Finally, the details of the 
methodology are introduced. 
2.2 Density Functional Theory (DFT) [2.1-2.3] 
Density functional theory (DFT) is not based on the wavefunction as the ab initio 
methods such as Hartree Fock method, but rather on the electron density function, 
p(x，y，z). Based on the two famous Hohenberg and Kohn (HK) theorems, DFT 
provides a sound basis for the development of computational strategies for obtaining 
different atomic and molecular information. 
The first HK theorem states that all the properties of a molecule in a ground electronic 
state are determined by the ground state electron density function p(x，y,z). While the 
second HK theorem states that any trial electron density function wi l l give an energy 
higher than or equal to the true ground state energy i f the functional used is exact. 
This suggests possibility of introduction of variational approach in DFT to calculate 
the energy and electron density. 
After HK theorem, practical treatment of DFT was provided by Kohn and Sham (KS) 
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theorem, which brought a key breakthrough to the DFT computational study. 
2.2.1 Kohn-Sham Theorem 
Kohn and Sham introduced the idea of non-interacting system of electrons to simplify 
the calculation: 
The energy functional is expressed as 
EWr)] =T„i[p(r)] + VneLoM + VeeWr)] + A T W r ) ] + A V e e [ p ( r ) ] (2.2.1.1) 
where Tni[p(r)] is the kinetic energy of the non-interacting electrons 
Vne[p(r)] is the nuclear - electron interaction 
Vee[p(r)] is the classical electron-electron repulsion 
AT [p(r)] is the correction to the kinetic energy deriving from the interacting 
nature of the electrons 
AVee [/o(r)] is the non-classical corrections to the electron-electron repulsion 
energy 
The strategy of the KS theorem is to regard the energy of the molecule as a deviation 
from the ideal energy (non-interacting electrons system), which the exact energy 
functional of the latter is known. Thus, only a relatively small discrepancy, AT[p(r)] 
and AVee[/o(r)], would contain the unknown functional. Sometimes, AT[/o(r)] and 
AVee [/o(r)] would be combined together and denoted as exchange-correlation energy 
(Exc[p(r)]). 
Since for an ideal system, the electron kinetic energy of the system is equal to the sum 
of the individual electron kinetics energies and the electron density of the system is 
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the sum of the Slater-determinantal wave function, i.e. 
P = t { x A X i ) (2.2.1.2) 
i=l 
Thus, within the orbital expression for the density, we can write: 
^ f / 1 \ / nuclei 7 \ � 
I \ , k | r i - r k | " (2.2.1.3) 
？〈不丨去 J 爲 d r U i 〉 + E J p ( r ) ] 
where N and k are the number of electrons and nuclei respectively. 
By minimizing E[p(r)] with respect to orbital % KS equation is obtained: 
(2.2.1.4) 
where Kohn-Sham (KS) one-electron operator is defined as 
f ^ ^ d r ’ + V x c (2.2.1.5) 
2 1 r i r ^ - r j J | r i - r ’ | -
and exchange correlation potential, Vxc, is defined as 
字 （2.2.1.6) 
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2.2.2 Exchange-Correlation Energy Functional 
The exchange-correlation energy functional, Exc, consists of two parts of components: 
Exchange-energy functional (Ex) and Correlation-energy functional ( E c ) , i.e. 
Exc = Ex + Ec (2.2.2.1) 
There are many energy functional available for the computational research. In this 
study, functional BP86 (Becke 1988 gradient corrected exchange functional [2.4] with 
Perdew 1986 correlation functional) [2.5] and mPWlPW91 (One-parameter hybrid 
functional using modified Perdew-Wang's 1991 exchange and correlation functional) 
[2.6] were used. 
2.3 Basis Set 
Basis set is a set of mathematical functions, linear combination of which yield 
molecular orbitals. In this work, three basis sets were employed: LanL2DZ, 
AUG-cc-pVDZ and SDD. 
2.3.1 Relativistic Effective Core Potential [2.7, 2.8] 
In order to achieve a reasonable effectiveness of the calculation involving platinum 
atom, basis sets with relativistic effective core potential were employed: LanL2DZ 
[2.9] and SDD [2.10]. Since atoms from about the third row of the periodic table 
contains large number of electrons. Calculations involving those atoms are not 
efficient i f all of their electrons are considered. To avoid this problem, a one-electron 
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operator is added to take into account the effect of the chemically mostly inert core 
electrons on the valence electrons, which latter are still considered explicitly. This 
operator is called an effective core potential (ECP) or pseudopotential. In addition, 
since the velocity of the core electrons in the heavy atoms are exceptionally high. 
Relativistic effects are required to be incorporated to correct for the effect of velocity 
dependence of the electron mass. In this sense, relativistic effective core potential are 
developed to handle calculation of the heavy atoms. 
LanL2DZ and SDD differ in the schemes of fitting the ECP to Gaussian functions, 
also the ways in treating the light atoms and valence atom are not the same. 
For LanL2DZ, it treats the first row elements using the Dunning/Huzinaga valence 
double-^ (D95V) and from the elements Na to Bi, it uses Los Alamos ECP plus DZ. 
For SDD, it treats the elements from H to Ar using the D95V and the remaining 
elements using the Stuttgar/Dresden ECP. [2.11] 
2.3.2 Double-Zeta 
The word double-广 or the "DZ" in LanL2DZ is actually the same with word 
Double-Zeta. It is often used to encounter a problem that minimal basis set has the 
limited variational flexibility especially when the exponents are not optimized. 
Actually, double zeta basis contains two functions for each of the basis function i.e 
doubling the number of the basis functions. The increase number of basis functions 
serves to improve the variational flexibility and hence the accuracy of the calculation. 
[2.12] 
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2.3.3 Polarized Basis Set [2.13] 
In this work, the Dunning's correlation consistent basis set augmented by diffuse 
functions (AUG-cc-pVDZ) [2.14-2.16] was used for the calculation of the dipole 
moment and polarizability (except for the platinum atom). The aim of using this 
polarized function is to simulate well the polarization behavior of the system, which is 
very important for the accuracy of the dipole moment and polarizability. 
With the definition of cc-pVDZ，the following polarized functions are included: 
H and He 2s, Ip 
B-Ne: 3s, 2p, Id 
Al-Ar: 4s, 3p，Id 
Also, by the keywords "AUG", the basis sets are augmented by adding the s, p, d 
diffuse functions with optimum exponent to the original cc-pVDZ basis functions. 
[2.11] 
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2.4 Solvation Model 
In this work, several solvation models were employed to mimic the real condensed 
phase effect on the platinum compounds that in real situation the compounds are 
surrounded by shells of water molecules. The Polarizable Continum Model (PCM) 
with different radius parameters available in Gaussian Computational Package and the 
continuum solvation model employed by Pang in this group were used in this work to 
encounter the important solvation effects. 
2.4.1 Continuum Model 
Actually, there are many different models to describe the solvation effect. The most 
"direct" way seems to be the model with a number of solvent molecules build 
explicitly around the solute molecule. However, in additional to the first solvation 
shell, several successive solvation layers should be considered so as to obtain a 
meaningful result. This makes the system becoming enormous in size. Also, with so 
many molecules and possible minima, great computational effort is needed to 
compute statistical mechanical averages in order to determine equilibrium properties. 
Expensive quantum calculations required by the explicit models led to the necessary 
development of models that require less computational resources. 
Continuum solvation models were developed for this purpose. With the continuum 
models, one may remove the huge number of individual solvent molecules from the 
model. To replace the explicitly charge distribution, a continuous electric field 
(continuum) that represents a statistical average overall solvent degrees of freedom at 
thermal equilibrium is used. Therefore, the introduction of the continuum model 
greatly reduces the cost of computational effort comparing with the "direct" explicit 
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model. [2.17] 
In this work, continuum models were employed to incorporate the solvation effect in 
the calculation. Simple solvation model employed by Pang is introduced first to 
provide the general idea of the continuum models, then the PCM models which is the 
main tool in this work is introduced. 
2.4.1.1 Simple Solvation Model 
Actually, free energy of solvation can be divided into the following three terms [2.17]: 
AGsoI = AGes + Gdr + G cav ( 2 . 4 . 1 . 1 . 1 ) 
where AGes represents the electrostatics interaction between the solute and the 
solvent continuum 
Gdr represents the dispersion-repulsion contribution to the solvation energy 
Gcav represents the energy cost of the cavity creation in the medium 
Here, introduction of each term in the simple solvation model is provided 
successively: 
2.4.1.1.1 Electrostatic Component [2.17] 
The net energy gained by the electrostatics interaction between the solute and solvent 
is given by: 
G =去 ( 2 . 4 . 1 . 1 . 1 . 1 ) 
where /o(r) is the solute charge density 
0(r) is the electrostatic potential in the medium 
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AGes is given by the difference of the net electrostatic energy gain in the solvent 
medium and in the vacuum, i.e. 
AGes = Gsolvent —Gvacuum ( 2 . 4 . 1 . 1 . 1 . 2 ) 
where the dielectric constant of the solvent medium is e and vacuum is 1. 
The heart of the continuum solvent models is given by the Poisson equation which 




The electrostatic term employed in the simple solvation models is actually the sum of 
the Bom equation and the Kirkwood-Onsager-reaction field equation: 
AGes = AGeom +AGKirwood-Onsager ( 2 . 4 . 1 . 1 . 1 . 4 ) 
Actually, the two equations are derived from the equations 2.4.1.1.1.1 and 2.4.1.1.1.3 
with the models of ideal cavities. 
Consider the model of a conducting sphere with charge q and radius a, the charge 
density at the surface of the sphere is given by: 
p = — ^ ( 2 . 4 . 1 . 1 . 1 . 5 ) 
with electrostatic potential on the surface is given by equation 2.4.1.1.1.3: 
— - i (2.4.1.1.1.6) 
ea 
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By applying the equation 2.4.1.1.1.1 with (j) and p, we obtain: 
G = - f - i ds =丄 (2.4.1.1.1.7) 
2 \ 4 7 r a A e a � 2ea 
where s is the surface point 
By the difference of G in the solution and gas phase, we have the Bom equation 
(2.4.1.1.1.8): 
I f , i V . 一一 e2Na「i n T r l、 
AG Bom =_一 1一_ (in atomic unit) = 1 - - (inJmol ) 
2 V 6 j a 87r6oa ^ e J 
where e is the electron charge 
Na is the Avogadro's constant 
€o is the vacuum permittivity 
I f stead of carrying a charge, the sphere now possesses a fixed dipole moment, fx, we 
have the Kirkwood-Onsager equation (2.4.1.1.1.9): 
A G K 一 一 二 - ( i n atomic u n i t ) = 錄〔益 )（ i n J m o l - i ) 
Therefore, the combined use of the two equations enables us to handle both the case 
of charged species and neutral species with fixed dipole moment. 
2.4.1.1.2 Dispersion-Repulsion Interaction [2.18] 
This energy term related to the induced-dipole-induce-dipole interaction and the 
repulsive forces between the solute and solvent molecules. With spherical symmetry 




G d r = N a J"E(r)47ir2pg(cj2，r)^/r (2.4.1.1.2.1) 
CJi2 
where g(a2,r) is the radial distribution function which measures the probability of 
finding a solvent molecular centre at the distance from the center of a solute molecule 
of hard sphere radius 02. In this work, the g(a2，r) is taken to be unity as suggested by 
the original paper of Scaled Particle Theory. 
The integral 0\2 is the sum of the radius of solute and solvent. The term E(r) is the 
interaction energy of a solute molecule with a given solvent molecule. In this work, 
the Lennard-Jones potential is chosen for the term E(r). [2.19] 
E(r) = - ^ + % (2.4.1.1.2.2) 
r 6 r l 2 
c 
The first term ——is the London formula for the induced-dipole-induce-diople 
r6 
(^ 3 I j I2 CL\ a2、 
interaction with Ca =——7 r " 6 t 2(11+12) J 
In the expression of Ce, Ii and I2 are the ionization potentials of the solute and solvent 
molecules respectively. And CL\ and AI are the polarizability of the solute and solvent 
molecules respectively. 
The second term — ^ represent the repulsive force, this term become dominant 
ri2 
when the intermolecular distance, r, is small. 
At equilibrium state of the solution, the attractive interaction between the solute and a 
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given solvent molecule is equal to the repulsive force between them. That means we 
can use the minimum point of Lennard-Jones potential well to represent the E(r) in the 
Gdr term. By taking the derivative of Lennard-Jones potential with 泥 ⑴ = 0 , we can 
dr 
obtain: 
E(r) = 」 与 （2.4.1.1.2.3) 
2 
By suitable substitution and integration, we get: 
2Na TTpCfi 
G d r = S — ^ ( 2 . 4 . 1 . 1 . 2 . 4 ) 
This is the second term of the simple solvation model employed in this work. 
2.4.1.1.3 Cavitation Energy [2.18] 
Cavitation energy encounters the energy required to create the cavities for the solute 
molecules. By the Scaled Particle Theory, the cavity could be created through a 
statistical fluctuation of the fluid (solvent) particles. The probability for such a 
fluctuation is given by: 
-w 
P = e k T ( 2 . 4 . 1 . 1 . 3 . 1 ) 
where W is the reversible work required to produce a cavity. 
By the suitable statistical calculation and algebraic manipulations, one can obtain the 
expression for the work and hence the third energy term in the simple solvation model 
( 2 . 4 . 1 . 1 . 3 . 2 ) : 
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kT [ l - y ) 1 - y 2 ( ^ 1 - y j pkT 
where p is the number density of the fluid (water) particles. 
P is the pressure exerted on the system 
Trpa? , „ 
y = ‘ and R = — 
6 
with a l and a2 represent the diameters of the solute and solvent hard sphere 
respectively. 
2.4.1.2 Polarized Continuum Model (PCM) [2.20-2.22] 
In the framework of PCM model, the solute molecules are embedded in cavities of 
molecular shape surrounded by a continuous dielectric medium. The molecular shape 
cavity is built with interlocking spheres centered on atoms: 
solvent , , solvent probe .,, ‘ , V ^ accessible 
sphere surface 
J ；1 • \ solvent 
/ y / ^ ^ (/ • y.4-excluding 
J surface 
van der Waals-surface 
Figure 2.4.1.2.1 Schematic Diagram of the Molecular Shape Cavity Constructed by PCM Model 
Adapted From web page:http://wwwxup.uni-muenchen.de/oc/zipse/compchem/solv/pcm.html 
Each solute atom or group is assigned with a van der Waals radius. The cavitation 
energy is computed using the van der Waals (vdW) surface, formed by spheres 
centered on atoms or groups with proper radii. Gdr is calculated with the solvent 
accessible area described by the center of the solvent probe sphere with radius equal 
to the "molecular radius" of the solvent rolling on the vdW surface. 
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For the electrostatic term, PCM uses an approximate version of the solvent excluding 
surface constructed by a scaling the vdW surface by a factor > 1，then the resulting 
surface is smoothed by some more spheres not centered on atoms. The surface of the 
solute cavity is divided into many small surface elements (tesserae) with each 
carrying the apparent point charge at the center of the area. These point charges 
determine the mean solute-solvent interaction potential,厂(平)，which is incorporated 
into the Hamiltonian operator of the molecular system to include the polarization 
effect of solvation: (note: only electrostatics energy term wi l l be included in the 
Hamiltonian) 
S e s = 卜 一 去 中)中〉 （2.4.1.2.1) 
The Hamiltonian can be written as: 
= 厂 ( 2 . 4 . 1 . 2 . 2 ) 
H ^ is the Hamitonian of the isolated molecule. And the gas phase energy of the 
molecules according to the Schrodinger equation is: 
芯0 =〈vp0H0xj/0〉 （2.4.1.2.3) 
While the simple solvation model employed in this work is not a self-consistent 
method, PCM model is the self-consistent reaction field (SCRF) method. The 
nonlinear relation between 平 and V is treated iteratively until the condition of 
self-consistent is obtained. 
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Finally, the free energy due to electrostatic interaction can be obtained: 
AGes =Sel-E® (2.4.1.2.4) 
and hence the free solvation energy: 
AGsol = AGes + Gdr + G cav ( 2 . 4 . 1 . 2 . 5 ) 
Actually, in Gaussian Computation Software, several models are available to provide 
different topology and sets of atomic radii for the construction of the molecular shape 
cavity. In this work, the United Atom Topological Model (UAHF), United Atom 
Topological Model (UAKS) and radii from the UFF force field (UFF) were employed 
in the calculation. Details of each model please refer to the reference directed [2.23]. 
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2.5 Methodology 
2.5.1 Calculation of DFT Global Reactivity Index 
In the first part of the project, DFT global reactivity index - chemical hardness (rj), 
was calculated as the QSAR parameter.(This is the continuous work of the Pang 
Project) Al l the searchable and named platinum drugs with GI50 data of 60 human 
cancer cell lines available in the NCI web pages were chosen for the QSAR study. 
Recall the definition of the chemical hardness from 1.4.1.5: 
^ _ Slump 一 SHOMO 
” 2 
From the definition of chemical hardness, information required to be extracted from 
the calculation are the orbital energies of HOMO and LUMO. 
Guest geometry of each platinum compound for optimization was built according to 
the information provided by the NCI web pages or the directed references. With the 
program Gaussian 98, the full geometry optimization to locate the energy minima 
(equilibrium structures of the molecules) was performed using DFT method with 
functional BP86, basis set LanL2DZ. The keyword command for the optimization in 
Gaussian 98 is O P T , the default algorithm for the optimization is the Bemy algorithm 
using redundant internal coordinates. [2.24] The convergence criteria for the 
optimization were the default setting in Gaussian 98. 
After the geometry optimization, PCM solvation model was applied to incorporate the 
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effect of solvent (water) on the energies of orbitals HOMO and LUMO. Using the 
same functional and basis sets as gas phase optimization, keywords SCRF (PCM, 
Read) were used to specify the program to perform the PCM reaction field 
calculation using the polarizable dielectric model. [2.20, 2.21, 2.25]. With the 
keyword Read, several additional parameters for the solvation were input into the 
calculation. They were 1.) temperature, 310.15K (37°C) was chosen for the system 
(TABS=310.15); 2.) dielectric constant of water at 310.15K, the value 74.152205 was 
used (EPS=74.152205). Actually, it was calculated by the equation given by 
Malmbery and Maryott [2.26](2.5.1.1): 
Sr = 87.740-0.4008T + 9.398xlO""^ T^-1.410x10"^ T^ 
and 3.) choice of radii model, UAHF model was used in this part of study 
(RADII=UAHF). 
The convergence criteria for the PCM calculation were the default setting in Gaussian 
98. 
Sometimes, the PCM calculation cannot be converged and minimal adjustment of the 
default calculation parameters was done to obtain the convergence. Usually, the 
parameters that could be adjusted are RET, which sets the minimum radius (in 
Angstroms) of the "added spheres" (0.2 is the default setting); TSUM, which sets the 
number of tesserae on each sphere (60 is the default for the usual 
pentakisdodecahedron which is the default polyhedron for each sphere); and TSARE, 
which sets the area of the tesserae (in 人2) (0.4 is a typical value). 
(Note: the program wil l automatically select the best polyhedron for the sphere with 
the specified TSUM or TSARE.) 
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After computational calculation, the energies for the HOMO and LUMO of the 
platinum compounds being studied were extracted and substituted into the equation 
1.4.1.5 to obtain the corresponding chemical hardness. While the data of GI50 was 
obtained from NCI web pages, and the average of log (GI50) from different cancer cell 
lines was used for the QSAR study. 
2.5.1.1 Calculation for the Reaction Intermediates 
Among the platinum compounds employed in our QSAR study, the platinum 
compounds with dichloride as the leaving ligand were further studied. The QSAR 
parameters (mentioned above) of their possible biological intermediates were also 
calculated. The intermediates chosen for the calculations were (Figure 2.5.1.1.1): 
In hydrolysis pathway: 
厂 "1 + 
L\ OH, 
/ P I 
L CI 
In methionine pathway: 
1— —I + 
C H , 
\ 3 
/Pt、 > 
L N H ~ ~ ( 
人 C〇2H 
where L is the carrier ligand of the platinum drugs studied 
For both species, they are the active intermediates responsible for the reaction with 
the first guanine in each pathway according to the computational study of DNA 
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binding mechanism by Pang in this group. The reason for this further investigation is 
to figure out the relative importance of the chemical hardness of their parent platinum 
drugs and their possible important intermediates on the overall activity (GI50). A better 
QSAR may be provided by using the parameters obtained from the more "actual" 
active intermediates, instead of their parent compounds. Guest model structures for 
the intermediates were built according to the figure 2.5.1.1.1 above and all the 
calculation methods employed were the same as their parent compounds. 
2.5.2 Calculation of the Reaction Pathways 
By the results of the first part, it was found that the potency of platinum drugs depend 
on the chemical hardness (rj) of their parent drugs rather than the chemical hardness of 
their corresponding possible intermediates. Chemical hardness actually is a parameter 
that can reflect chemical reactivity [1.37]. Hence, chemical reactivity of the parent 
compounds of platinum drugs is important. Thus, in the second part of this work, 
chemical reactivity parameters (both thermodynamics and kinetics) of the parent 
compounds were investigated for the further QSAR study. The free energy change 
(thermodynamics) together with the corresponding activation energy (kinetics) for the 
first reaction step in the three possible biological pathways (direct binding pathway, 
hydrolysis pathway and methionine pathway) were calculated in this part: 
Direct binding pathway: 
O 
(A): L>(CI + 《 N j ^ J f H _ _ ^ 「 : 〕 p ( l 丫 + c「 
H N NH2 NH 
4 2 
Hydrolysis pathway: 
k .CI � L \ "1 + 
(B)： pt + H2O ^ pt + cr 
, / 、 / 、 
L CI L OH2 
Methionine pathway: 
— —I + ( C ) : : > C + H ^ s Y o h ^ + CI-
NH2 H3C NH2 




^ / 』‘ products 
/ AG 
/ - i _Y_ 
reactants 
Reaction Coordinate 
Figure 2.5.2.1 Energy Profile of the Reaction Study 
AG(reaction) = G (products) - G (reactants) (2.5.2.1) 
AG^(reaction) = G(transition state) - G(reactants) (2.5.2.2) 
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Since the platinum(II) complexes has the d^ electronic configuration. Its nucleophilic 
substitution involves the attack of the nucleophile to the empty pz orbital on either 
side of the square plane. From the evidence of reaction rate law, reaction rate 
dependence on nucleophility of solvent and steric effect of the ligands, and also the 
thermodynamics data on the entropies and volumes of activation, AS^ and AV言’ it is 
believed that the square planar platinum complexes would undergo the nucleophilic 
substitution reaction through a association pathway. And besides being attracted to the 
electron deficient platinum center, the ligand will experience repulsion from the filled 
d orbitals and from the bonding electrons. The reaction therefore proceeds through 
trigonal bipyramidal transition state: (Figure 2.5.2.2) [2.27] 
Li 1-1 Li 
, T , T 
Y + y , Y S . y + X 
x Z � X Y ^ 
L2 L2 
where Y is the entering group, X is the leaving group and T is the trans ligand. 
Figure 2.5.2.2: Mechanism for Nucleophilic Substitution for the Square Planar Platinum Compounds 
Therefore, square planar platinum products together with the trigonal bipyramidal 
transition state complexes were built according to the above reaction schemes. DFT 
method BP86 with basis set LanL2DZ was applied for the full geometry optimization 
with Gaussian 98. Keywords OPT(TS) was used for the transition state optimization. 
Resulting optimized transition state was verified by having one imaginary frequency 




Figure 2.5.2.3: Vibration Pattern of the Imaginary Frequency for the Transition State 
This vibration pattern showing the opposite direction of ligand Y and X towards the 
platinum center can provide the identification of whether the transition state structure 
is corresponding to the substitution reaction of Y and X. 
The total energy computed by a geometry optimization is the minimum (reactants and 
products) or the saddle point (transition state) on the potential energy curve. To 
obtained the actual free energy of the species, thermochemical analysis that introduces 
the zero-point energy correction and the thermal corrections to the Gibbs free energy 
was done by applying the vibrational frequency calculation using the keywords Freq 
=Readlsotopes. With Readlsotopes as the option to the keyword Freq, temperature, 
pressure and the scale factor for the frequency data can be specified for the 
thermochemical analysis. In this work, 310.15K, l.Oatm and 1.0 were chosen as the 
corresponding parameters for the thermochemical analysis. 
After the Freq calculation, solvation energy was calculated to add the solvation effect 
on the gas phase free energy obtained above. In this part of the work, two solvation 
models were used. They were the PCM model with the radii UAHF using Gaussian 
03 and the simple solvation model adopted from Pang's work using Gaussian 98. 
Gaussian 03 now uses the integral equation formalism (lEF-PCM) as the default 
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setting for the reaction field calculation. Moreover, with several new formalism 
implementations, this version claimed to have significant improvements in the 
performance and accuracy for the PCM calculation. In this part of the work, since the 
molecular size of the reaction products and transition state were significantly larger 
comparing with their parent compounds, the problem for the SCF convergence as 
mentioned above became serious. This showed that the PCM in Gaussian 98 was not 
suitable for those large molecules. With the improvement in SCF convergence and 
ability in handling the large molecular system, version Gaussian 03 was employed to 
perform the PCM calculations.[2.22] 
Keywords SCRF(PCM, Read) were used with parameters EPS=74.152205, 
TABS=310.15 and RADII=UAHF which were the same as in the Gaussian 98 
calculation. 
For the simple solvation model adopted from Pang's work, several parameters and the 
information obtained from the computation are required to plug into each energy 
term: 
For the electrostatic interaction (equation 2.4.1.1.1.8 and 2.4.1.1.1.9): 
Dipole moment, fX, in the Kirkwood/Onsager term was determined by the DFT 
method BP86 using AUG-cc-pVDZ as the basis set with keyword Polar. Dielectric 
constant, e, at 310.15K was used as mentioned before. The term "a" in the expression 
was the radius for the ideal sphere. The ideal hard sphere diameter of each molecule 
(except water and chloride) was taken as the greatest intemuclear distance with the 
addition of the van der Waal's radii (from Bondi, A.) [2.28] of the two involved atoms. 
[2.29]. The water hard sphere diameter was 2.8人 based on X-ray diffraction [2.30], 
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and chloride was 1.81 人[2.31] based on the effective ionic radius obtained from the 
crystal structure[2.32]. 
For the Cavitation Energy term (equation 2.4.1.1.3.2) 
The number density of the water, p, was corrected for 37°C using the equation for 
thermal expansion of water: 
N 
P = v r ^ (2.5.2.3) 
Vni(37。C) 
where Vm(37。c) = ^m(25°C) +/^water x(37-25)] 
Given the molar volume of water at 25°C, ¥1^(25° C)，is equal to 18.07 cm^mor' and 
thermal expansion coefficient of water, /?water, is equal to 0.257 x 10"^  °C. [2.18] 
For the Dispersion-repulsion interaction (equation 2.4.1.1.2.4) 
In the C6 attractive term, the polarizabiltiy, a, was determined by the Polar calculation 
with BP86/AUG-ccpVDZ. The ionization potential, I, was determined by energy of 
HOMO orbital (I 〜CHOMO) by Hartree-Fock (HF) method with LanL2DZ as the basis 
set. The use of HF method here was to avoid the use the Kohn-Sham orbital which 
may under-estimate the 6HOMO.[2.33, 2.34] 
The calculated solvation energy was then incorporated into the gas phase free energy 
to obtain the free energy in solution: 
Gsol = Ggas + Gsolvation ( 2 . 5 . 2 . 3 ) 
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Therefore, the free energy and the activation energy for the studied reaction can be 
obtained: 
AGsoi(reaction) = Gsoi (products) - Gsoi (reactants) (2.5.2.4) 
AG^soi(reaction) = Gsoi(transition state) 一 Gsoi(reactants) (2.5.2.5) 
In the final part of this project, the corresponding pathway reactions of the five 
Pt-DMC (platinum drugs with demethylcantharidin) compounds synthesized by our 
group and carboplatin were studied. The aim is to test i f the established results in this 
work can be applied to another type of platinum drugs with carboxylate bidentate 
leaving ligands. The first step of direct guanine binding pathway of those compounds 
was studied. DFT methods BP86/LanL2DZ and mPWlPW91/SDD were employed 
for the calculation. Simple solvation model adopted from Pang's work in Gaussian98 




Overall QSAR Analysis for Platinum Drugs Using Chemical Hardness 
3.1 Introduction 
The aim of this project is to establish an overall QSAR picture for platinum drugs 
using available biological data from the NCI. Pang of this group started the 
calculation of chemical hardness of platinum drugs using available NCI data. This 
thesis picks up where Pang had left off, therefore, in the first part of the project, 
calculation for platinum compounds not covered in Pang's thesis was carried out. 
Here, this thesis also explores the QSAR of possible biological intermediates of 
platinum drugs as means of understanding the observed trend in biological system. 
3.2 Optimized Structure Against Experimental Geometry 
In his early work, Pang compared the calculated structures against the X-ray crystal 
data for cisplatin, carboplatin, oxaliplatin, guanine and methionine. The results 
suggested that the DFT method BP86/LanL2DZ is satisfactory in predicting the 
geometry of these compounds [3.1]. 
In this QSAR study, different types of platinum complexes were considered. 
Therefore, geometry validation for other types of platinum complexes was required. 
With the available x-ray crystal data, four platinum compounds were selected to 
represent four types of compound other than cisplatin, carboplatin and oxaliplatin. 
They were transplatin (complex with trans ligands)[3.2]，Z^w-aziridine dichloro 
platinum(II) (complex with freely rotating carrier ligands other than amine) [3.3], 
cis-amminedichlorocyclohexlamineplatiunm(II), JM118 (complex with asymmetric 
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carrier ligands) [3.4] and tetraplatin (platinum(IV) complex).[3.5] 
丽 y C l ^ N H CI / \ X 
CI NH3 ^ ^ N H CI 
Transplatin Z?z5-aziridine dichloro platinum(II) 
/ C I CI 
/ ~ \ 八 
( ) N H , CI 
JM118 Tetraplatin 
Figure3.2.1: Chemical Structures for the Compounds in X-ray Data Comparison 
Figure 3.2.2 shows the optimized gas phase structures for the selected complexes, 
bond length and bond angles calculated by BP86/LanL2DZ (green) are compared 
with experimental x-ray crystal data (black). 
Transplatin: 
^ (88.5) 
(91.5)92.0 (2 05) 92.0(91.5) 
(88:5) 
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• • ( 1 2 3 . 9 ) / ' ' x T (1.55) 
124.2 / W V v i Z ^ 
l y i W ^ ^ C ) (128.6) O 
1.51 C y 
JM118： (91.9) 
97,0 
^ ^ ( 2 . 3 0 ^ ^ 
^ (2.30) 2A\JF 
(88.3)81.3 (2.06) F ^ (88-7) 
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】 0 . 5 1 ) O 
O f 
i V l ^ i / 11 .55 (1 .52) 
P ( 1 1 7 . 0 ) 飞腊） I ^ ^ 
\ V n o . s O 
O (110.4) 
w 
(109.3)111.5 1 (110.2) 
10.8 (107.8) 
Tetraplatin: 
(89.3) 96.3 ( ( l ^ ^ l l ^ & f j l l s i h T75 (1 .41S) 
(90.4)攀 U Q 
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10.8 (114.3) 
93.0 V 2 F 111.5 (110.7) 
(89.7) o … 
O (108.5) 
H 〇 C 0 N 0 C 1 0 P t 0 
Figure 3.2.2: Gas Phase Geometry by BP86/LanL2DZ and X-ray Crystal Results 
Comparison shows that the geometries obtained using the BP86/LanL2DZ theoretical 
calculation correlate well with the experimental data. Except for the Pt-Cl bonds, 
which consistently gave a significantly longer bond length when compared with the 
bond length extracted from x-ray structures (BP86/LanL2DZ -2.4 入，x-ray data -2.3 
A). Deviations between calculated and x-ray bond length generally do not exceed 0.1 
A. The great deviations of one Pt-N bond (0.21 A) and one N-C bond (0.26 A) in 
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Z?z5-aziridine dichloro platinum(II) might be attributed to the strong interaction with 
the adjacent molecules which is not encountered in theoretical gas phase optimization. 
[3.3] 
In the bond angle comparison, results show that the theoretical calculations could 
reproduce the x-ray crystal bond angle except for the case of JM118. The deviations 
of the bond angles on the Pt-Cl-N plane in JM118 were found to be relatively larger 
(max 〜9 A), this was similar to the results obtained from cisplatin. [3.1, 3.2]. For the 
case of cisplatin, the deviations are attributed to the intermolecular hydrogen bonding 
between the ligand NH3 and CI. Therefore, it is reasonable to believe that similar 
hydrogen bonding exists in the case of JM118 and results in the relatively large bond 
angle deviations. To summarize, the DFT method BP86/LanL2DZ is the legitimate 
tool for the geometry optimization in our QSAR study. 
3.3 Kohn-Sham Orbitals: 
The DFT reactivity indices employed in this work were constructed by the energies of 
HOMO and LUMO of Kohn-Sham (KS) orbitals. Although the debates in the physical 
significance of the KS orbitals remain continuous, several authors believed that the 
KS orbitals do connect to the real world system by the properties to yield the exact 
electron density and the inclusion of the electron correlation effects [3.6]. It was 
shown that i f the exact exchange-correlation functional is employed, the HOMO 
energy of the KS orbital is equal to the ionization potential approximated by 
Koopman's theorem [3.7]. For the LUMO energy, it does depend on the size of the 
basis set used, fortunately, it appears that relative values for a series of related 
molecules are often quite reliable [3.8]. 
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3.3.1 Location of the HOMO and LUMO 
In order to illustrate the DFT reactivity parameters employed in this work can be used 
to reflect the reactivity of the platinum center, orbital calculations were performed to 
illustrate the location of the HOMO and LUMO that are the orbitals responsible for 
the reaction. Typical case for cisplatin is taken for the illustration (Figure 3.3.1.1) 
HOMO of cisplatin: 
_ Cl-side _ 
N-side Cl-side N-side 
View from the top View from the side 
LUMO of cisplatin: 
Cl-side 一 
N-side Cl-side N-side 
View from the top View from the side 
Figure 3.3.1.1: 3D location of the HOMO and LUMO of Cisplatin 
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In a nucleophilic substitution reaction of the platinum complex, the electron density of 
the attacking nucleophile would enter the LUMO of the platinum complex, the 
existence of portion of LUMO on the platinum center provides a chance for the 
platinum center to accept the incoming electron density from the attacking ligand. 
While HOMO is the orbital that contains electrons with the highest energy in the 
ground state. In cisplatin, the HOMO is located mainly on the platinum center and the 
leaving ligands. The location of the HOMO on the platinum center means that it is 
involved in the nucleophilic reaction of platinum complexes. 
Hence, the energies of the HOMO and LUMO affect the reactivity of the platinum 
center directly and the application of the DFT reactivity parameters becomes sensible. 
However, not all the calculated HOMO and LUMO can reflect the reactivity of the 
platinum center. For example in Figure 3.3.1.2 
Figure 3.3.1.2: Example of Compound with HOMO and LUMO not involved in the 
Reaction of Platinum Center: 
應 
o / n V^^Br 




Drug (44)： (1 ,2-cyclohexanediamine-N,N')bis[2-[(3-bromo-4-hydroxyphenyl)-
(3-bromo-4-oxo-2,5-cyclohexadien-l-yliden) methyl]-1 -benzenesulfonato-0]-, (SP-4-2)-,platinum(II) 
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The HOMO and LUMO of Drug(44) do not locate on the plane of the platinum center 
as cisplatin, instead, they are found on the highly conjugated system which is 
indicated by the blue circle. That means the HOMO and LUMO calculated in this 
case do not involve in the nucleophilic substitution on the platinum center, hence they 
cannot reflect the reactivity of the platinum center. Therefore this was not used to 
construct the QSAR of the platinum drugs. Similarly, by HOMO and LUMO location, 
some other irrelevant data can be excluded in the QSAR study so as to obtain a 
meaningful comparison of the chemical reactivity of the drugs. 
3.4 Results of the DFT Reactivity Parameter 
Table 3.4.1 tabulates the results of the QSAR calculations for the platinum drugs with 
NCI data available. Actually, NCI provides the screening data with wide set of cancer 
cell lines: The cancer cell types include Leukemia, Non-Small Cell Lung, Small Cell 
Lung, Colon, Central Nervous System, Melanoma, Ovarian, Renal, Prostate and 
Breast. [3.9] For each kind of cancer, several cell lines are used for the screening data, 
therefore, altogether the reliable screening data set is constructed with the results of 
about 50-80 cell lines for each compound. In this QSAR study, the average of the 
logarithm of the GI50 (concentration to inhibit 50% cancer growth) of cell line set was 
employed as the biological parameter. 
In addition, series of the Pt-DMC drugs synthesized by our group were also included 
in the QSAR study. The screening data was obtained from cancer cells (Leukemia: 
L1210), (Colon: COLO-320-DM), (Liver: MDA-MB-231), (Breast: MDA-MB-231), 
(Lung: NCI:H460), (Ovarian: SK-OV-3) and (Testicular: NTERA-Scl-Dl) for 
compound 1-4 [3.10]. For the Pt-DMC compounds with DACH ligands, data was 
57 
extracted from the cell lines (Liver: SK-Hep, Huh-7, PLC/5), (Colon: Colo320， 
HCT-116, HT-29), (Leukemia, L1210) [3.11]. The biological data for the Pt-DMC 
compounds was corrected by the difference in the results obtained for cisplatin in our 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.5 Chemical Structure of the Drugs in the QSAR 
Platinum (II) drug with dichloride lignds: (The no. in the parentheses is the drug no. according to the 
Table 3.4.1) 
飞 、 � > V T H , a � N 
^ N CI > = \ / C l 八 CI 
Drug(l) Drug (2) Drug (3) Drug (4) 
^ N H CI H3N CI ,C1 \ = J ^ N t ^ / C I 
\ t / I \ 八 
\ a N i / \ i a ci 
Drug (5) Drug (6) Drug (7) Drug (8) 
Dichloride platinum(II) drug with silyl-substituted amine: 
\ X~N々 /CI \ 厂 Nl^  /CI _ \ 厂 /C , 1 
> i > t > i 八 / S i Pt < 八 
Drug (15) Drug (16) Drug (17) Drug (18) 
Platinum(II) drug with dibromide lignds: 
� N S 
, O B, H 〜 , 





Platinum(IV) drug with silyl-substituted amine: 
<pi CI CI r , CI 
CI C. CI - C I C. 
Drug (19) Drug (20) Drug (21) Drug (22) Drug (23) 
Platinum(II) drug with DACH carrier ligand: 
CI 
Drug (24): cis-DACH, Drug (26): "•a/w-(S，S)-DACH，Drug (31):加aw-(R，R)-DACH 
0 
Pi〈 / /”NH, PtC^  FH ]j 
o 
Drug (25) Drug (27) Drug (28) Drug (29) 




Drug (30): trans-iS,SyDACH, Drug (32): rran5-(R,R)-DACH 
Platinum(II) drug with DMC leaving ligand: 
O 
Drug (33):炉fl/w-(S’S)-DACH，Drug (34): trans-(R,R)-DACli, Drug (39): cw-DACH 
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(Cl^ CHNH o ^ ^ V i N CH3CH,NH, Q ^ ^ V ^ CHaNI^、QA^^ 
p< 丫 i 〕 P< 丫 i 〕 < o I 9 
(CH3),CHNH/ Oy^M/^ CH3CH2NH/ O y ^ M ^ NH3/ CH3NH3/ 
o O 0 0 
Drug (35) Drug (36) Drug (37) Drug (38) 
Platinum(IV) drugs: 
八 严 N 、 
CI 
Drug (40) 
Other Platinum drugs: 
OH ° “ 
Drug (41) Drug (42) Drug (43) 
LXnA V ？P N、， 
T 
o 
Drug (44) Drug (45) 
/ T ^ v ？ 。 ？ 。 丫 。 
~ " ^ ， / C I t ^ N - F ' t - N ^ (^N-ft-NH3 
— 。 N H / 、 0丫。 。丫。 0丫。 
Drug (46) Drug (47) Drug (48) Drug (49) 
Figure 3.5.1: List of Chemical Structure of the Drugs in the QSAR 
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3.6 QSAR Analysis 
According to the calculated value of chemical hardness, the QSAR analysis for the 
platinum drugs was performed. Although the aim of the QSAR is to include all the 
searchable and named platinum drugs in which the biological data is available in the 
NCI database, we carried out a review to ensure data consistency but found that some 
data are questionable. 
These are grouped under the catalogue "Other Platinum drugs". Drug (41) was 
rejected from the study because the "Highest Dose Concentration" used in the 
screening test is 10'^  M, while the "Highest dose concentration" used was lO'^ ^M for 
all platinum compounds. It is found that the log (GI50) results obtained from the cell 
line screening using different "Highest Dose Concentration" deviated greatly from 
each other. For the sake of consistency, all the data employed in this work are 
obtained from the screening test using lO'^ ^M as the "Highest Dose Concentration". 
Drugs (42) to (45) were also uncovered from the data set because their HOMO and 
LUMO do not involve in the nucleophilic substitution on the platinum center, and 
hence the DFT parameters constructed by their energy would not reflect the reactivity 
of the platinum center as mentioned. 
In addition, the data for Drugs (46) to (49) were rejected because they are "inactive" 
in many cell lines. Since NCI would report the "Highest Dose Concentration" as the 
GI50 i f the drug cannot inhibit 50% cancer growth even when "Highest Dose 
Concentration" is used. I f there are many "inactive" cell lines in the data set, the 
average GI50 of the drug would be significantly overestimated. The criteria to accept 
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the average GI50 reported by the NCI is that the drug should not have more than 15% 
of cell lines in the data set with "Highest Dose Concentration" as the GI50. With this 
criteria, Drugs (46) to (49) were removed from the QSAR study. Also, the GI50 data 
for Drug (14)，carboplatin, do not fulfill the mentioned criteria, it was included in the 
analysis due to its importance in platinum anti-cancer drug chemistry. In addition, 
biological data of the Pt-DMC compounds does not come from the NCI, it is used 
here to test i f the constructed QSAR in this work can be reproduced for the smaller 
and different cell line data set employed by our group so as to explore the application 
of the QSAR on the drug design for the Pt-DMC compounds. 
3.6.1 The Overall QSAR Plot of the Platinum Drugs 
log(Gl5o) v.s. chemical hardness for platinum drugs 
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Figure 3.6.1.1： The Relationship between log(Gl5。）and Chemical Hardness of the Platinum Drugs 
The QSAR plot constructed by the correlation between log(Gl5o) of the platinum dugs 
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from NCI data and chemical hardness is shown in Figure 3.6.1.1. A general 
observed trend is that decreasing in the chemical hardness corresponds to decreases in 
the log(Gl5o). This implies that the potency of the platinum drugs increase as the 
chemical reactivity of the drugs increase (decrease in chemical hardness). It has 
been discussed in Chapter 1 that DNA is the ultimate biological target for the 
platinum drugs. Before the DNA alkylation, series of nucleophilic substitution occur 
according to each possible DNA binding pathways. Therefore, it is expected that 
platinum drugs with higher chemical reactivity may lead to the formation of larger 
amount of cytotoxic Pt-DNA adducts and hence possess higher potency. 
In the graph, the platinum drugs are divided into two regions: Platinum (II) and 
Platinum (IV) region. Note that platinum(IV) drugs operates a different biological 
mechanism from platinum (II) drugs. While the d^ octahedral platinum (IV) 
complexes are inert to substitution reaction, it is widely believed that reduction to 
platinum(II) is essential for the anticancer activity of platinum(IV) complexes to be 
effected Figure 3.6.1.2 [3.12]: 
X 
A〜,J、、、、Y 2e- A Y 
Pt > ^ P C 
、丫 、丫 
X 
Figure 3.6.1.2: Two Electrons Reduction from Pt(IV) to Pt(II), A: carrier ligand, Y: 
leaving ligand, X: axial ligand 
Therefore, platinum(IV) drugs do not undergo the nucleophilic substitution reaction 
directly while platinum(II) compounds do. The rationale of the correlation between 
69 
chemical reactivity and the potency of the drugs in platinum(II) chemistry may not be 
applied on the platinum(IV) drugs. Therefore, the inclusion of platinuin(IV) in the 
QSAR plot is purely from an empirical perspective. 
3.6.1.1 Empirical Applicability of the QSAR on the Platinum(IV) Drugs 
Except for the Drug (40), all platinum(IV) drugs in the DACH and silyl-substituted 
ammine type follow the qualitative trend that the potency increases as the chemical 
hardness decrease going across the platinum(II) and platinum(IV) region. This point 
can be easily seen by the connection of the platinum(IV) drugs to their corresponding 
platinum(II) counter part in the QSAR plot (Figure 3.6.1.1.1). 
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Figure 3.6.1.1.1: Empirical QSAR Trend from Corresponding Pt(II) to Pt(IV) Drug 
It IS observed from platinum(II) to platinum(IV), the log(Gl5o) of the drugs decrease, 
and the decrease in the log(Gl5o) correctly reflect qualitatively the decrease in 
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chemical hardness qualitatively. Therefore, from the empirical point of view, the data 
points of the platinum(IV) drugs is worthy of retaining in the QSAR study so as to 
provide a whole picture of the platinum drug QSAR. 
3.6.1.2 Detail QSAR Study According to the Type of Platinum Drugs: 
It is expected the potency of platinum drugs do not depend solely on the chemical 
reactivity of the compounds. Other effects may exist, that are independent of chemical 
reactivity, playing an essential role in the overall potency of drugs. One such example 
is uncovered in the Pt-(?ra«5-DACH) series of compounds as shown in Figure 
3.6.1.2.1. 
Figure 3.6.1.2.1: trans-DACK Ligand 
Unlike cisplatin, it is believed that this type of compounds undergoes a different cell 
death mechanism supported by observation of that response to the mismatch repair 
(MMR) mechanism for the Pt-DNA adducts is different.[3.13] From the QSAR plot 
(figure 3.6.1.1), it is demonstrated unambiguously that Pt-(rra«5-DACH) compounds 
possess higher biological activity than non-'Vra?i5-DACH" containing platinum drugs. 
This improvement in potency may be attributed to the undiscovered different cancer 
curing mechanism for the ？i-{trans-DACR) drugs which cannot be reflected by 
chemical reactivity (chemical hardness) of the compounds. Therefore, in presenting 
the first QSAR plot (Figure 3.6.1.2.1.1), the data points of ？{-(tmns-DACE) 
compounds are excluded to avoid complication in the analysis of the QSAR by the 
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"DACH" effect. 
3.6.1.2.1 QSAR Study of the non-“炒fl«s-DACH，，Platinum Drugs 
log(Gl5o) against chemical hardness of non-"trans-
DACH" Pt-drugs 
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Figure 3.6.1.2.1.1: The Relationship Between logCGIjo) and Chemical Hardness of the 
Platinum Drugs Excluding the "rran^-DACH" series of compounds 
The point Drug(40) is not shown due to its inability to empirical fit the trend. In the 
plot, it can be seen that except for Drugs(17) and (18), the data points in the plot 
forms a reasonable linear relationship between log(Gl5o) and chemical hardness. The 
different types of platinum compounds involved in this plot include 1.) • platinum(II) 
drug with dichloride ligands: Drug(l) to Drug(8). 2.)會 dichloride platinum(II) drug 
with silyl-substituted amine: Drug(15) to Drug(18). 3 . ) A platinum(II) drug with 
dibromide ligands: Drug(9) to Drug(ll). 4 . ) + platinum(II) drug with trans ligands: 
Drug(12) and Drug(13). 
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5.) •carboplatin: Drug(14). 6.) • platinum(IV) compound with silyl-substituted 
amine Drug(19) to Drug(23). platinum(II) drug with cw-DACH carrier ligand: 
Drug(24) 8.) - Pt-DMC compound: Drug(35) to Dmg(38). 
An initial inspection of the plot confirms that the Pt(IV) silyl-substitiuted compounds 
follow the semi-quantitative QSAR trend empirically, which strengthens the 
confidence to apply the use of chemical hardness to Pt(IV) complexes. Since, a wide 
variety of platinum compounds is incorporated within the trend, it means that a 
chemical hardness can be applied universally for drug design. This correlation opens 
the possibility of predicting the approximate GI50 or IC50 values using chemical 
hardness before synthetic work is carried out. 
The reason for the large deviation of the two silyl-substitiuted, coinpound(17) and 
(18)，from the main QSAR trend is uncertain. However, in the original publication in 
which the synthesis of the platinum silyl-substitiuted drugs were reported, the authors 
claimed that the synthesized drugs were evaluated by the NCI 60 human cancer cell 
line screening [3.14]. Therefore, comparison between results reported in that 
publication and in the NCI web-page was performed and is presented in Table 
3.6.1.2.1.1. To meaningful compared the data, the values of "log(Gl5o) in the NCI web 
page" were obtained by selecting the web page data from the 58 human cell lines 
employed in the publication of the 58 cell line data available, no more than 5 cell lines 
data are missing in the NCI webpage for each silyl-substitiuted drug. 
The comparison shows that the largest deviation is found for Drugs(17) and (18) 
between two sets of data (-0.45 and -0.54 respectively). While the deviation for the 
remaining platinum silyl-substitiuted drugs do not exceed 0.23. Both results shows 
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that the potency of Drugs(17) and (18) are higher than that of the Drug(15) and (16) in 
the platinum(II) silyl-substitiuted series, however, the potency difference between 
them is much larger in the results from the publication of compound synthesis. Note 
that the log(Gl5o) values obtained for Drug(17) and (18) in the original publication fit 
the QSAR trend reported here [Drug(17): -4.71 and Drug(18): -4.93], but we are 
unable to explain these discrepause with the data in the published NCI webpage. 
Table 3.6.1.2.1.1: NCI 60 human cell lines screening data of the eight studied Pt 
silyl-substituted drugs in the original paper and NCI web pages. 
Log(Gl5o) in the Log(Gl5o) in the Difference from 
Drug 
original paper NCI web-page two sets of results 
15 -4.69 -4.69 0.00 
16 -4.59 -4.74 -0.15 
17 -4.71 -5.16 -0.45 
18 -4.93 -5.47 -0.54 
19 -5.32 -5.26 0.06 
20 -5.35 -5.37 0.02 
21 -5.52 -5.52 0.00 
23 -5.38 -5.61 -0.23 
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3.6.1.2.1.1 QSAR equation of the non-"/rfl«s-DACH" Platinum Drugs 
logCGIso) against Chemical Hardness for the non-'ti-ans-
DACH" Platinum Drugs 
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Figure 3.6.1.2.1.1.1: QSAR Trend Line for the non-“/ra/w-DACH” Platinum Drugs 
Since the reliability of the data for Drugs(17) and (18) is suspected, they are removed 
from calculating the correlation coefficient for the QSAR trend line in figure 
3.6.1.2.1.1.1. 
The data for the Pt-DMC compound (pink square) are also excluded from fitting the 
QSAR trend line since their biological data do not come from the NCI 60 human 
cancer cell line screening data set. The resulting linear regression coefficient, 
R = 0.7798, shows a reasonable confidence of the QSAR equation. Because the 
biological activity does not solely depend on the chemical hardness, small deviation 
from the regression line may be expected and attributed to other parameters that are 
independent of chemical reactivity. Here the regression line coefficient shows that 
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chemical hardness and hence the chemical reactivity plays a dominating role in 
determining the biological activity the compounds investigated. 
As mentioned before, the biological data of Pt-DMC compounds came from different 
sets of cell lines. To test i f the QSAR constructed by the NCI 60 human cancer cell 
lines can be reproduced for a relatively small and different cell lines sets cancer 
screening, the data points of the Pt-DMC compounds obtained in this study is placed 
into the QSAR analysis. 
It is found that the Pt-DMC compounds reasonable obey the QSAR trend constructed 
by the NCI data. The lower value in log(IC5o) of the Pt-DMC compounds may be 
attributed to by additional biological activity of the demethylcantharidin (DMC)，the 
leaving ligand. DMC is a modified component of a traditional Chinese medicine, 
cantharidin, which has been used for the treatment of liver, lung, intestinal and 
digestive tract tumors in China. We show here that the synthetic analogue of 
cantharidin, demethylcantharidin (DMC), possess antitumor activity but without the 
adverse side effects of cantharidin. In the case of Pt-DMC, the anti-tumor effect of the 
DMC ligand takes effect upon dissociation from the platinum moiety in the biological 
system. [3.10] This additional anti-tumor activity contributed by DMC which cannot 
be reflected by the chemical hardness causes downward deviation of the log(IC5o) of 
the Pt-DMC drugs from the QSAR fit. 
Therefore the results show that the QSAR does reproduce well in the set of cell lines 
employed in this study, and future design of Pt-DMC compounds by utilizing 
chemical hardness may become feasible. 
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To summarize, the semi-quantitative QSAR equation for the non-"rra«5-DACH" 
platinum drugs is proposed to be: 
log(Gl5o) = (1.6494 X rj) -7.0588 (3.6.1.2.1.1.1) 
where GI50 is in unit of M and rj is in unit of eV 
3.6.1.2.2 QSAR Analysis for the Pt-trans-DACH Drugs 
In this section, the QSAR for the Pt-Ora/w-DACH) compounds is considered. 
Pt-DACH compounds represent a new generation of platinum anti-cancer drugs. 
Oxaliplatin, a widely used Pt-DACH drug, shows different activity profile and low 
cross-resistance from cisplatin. The ability of oxaliplatin to overcome the resistance in 
the cisplatin-resistant MMR deficiency cells suggests Pt-DACH drugs have a different 
mechanistic pathway in cancer curing. [3.13，3.15] 
MMR is a post DNA-replication repair pathway which corrects base mispairs arising 
during DNA replication. Actually, MMR mediates the anti-cancer activity of cisplatin. 
In MMR proficient cells, the MMR damage-recognition protein binds to the 
cisplatin-DNA adduct. This binding is followed by the removal of the newly 
synthesized strand by mismatch proteins. However, the Pt-DNA adducts in the parent 
Strand are not cleaved by this mechanism. The retention of the Pt-adducts leads to 
futile cycle of DNA mismatch repair and finally triggers cell apoptosis. [3.13] 
It was shown by Zdraveski et al. [3.16] that the MutS (the bacterial analogue of the 
human MMR damage-recognition proteins) can recognize cisplatin-DNA adducts 
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with twofold higher affinity than oxaliplatin-DNA adducts. This suggests the 
Pt-DACH drug functions in some what different ways from cisplatin, however, the 
molecular basis of oxaliplatin toxicity and its ability to overcome resistance have not 
yet been fully elucidated. This mechanistic difference generally refer to the "DACH 
effecf'is reflected in the significantly lower log(Gl5o) value for the Pt-(^ra«5-DACH) 
compounds. [3.13] 
Two geometrical isomers for the DACH ligands exist, they are the trans and the cis 
form. Of these, the /ra«5-DACH can be further sub divided into two enantiomers, 
Pt-(li?,2/?-DACH) and Pt-(15',25'-DACH), while the cis-DACH is the diastereoisomer 
Pt-(1 足2«S-DACH) as shown in Figure 3.6.1.2.2.1. 
NH2-
’ H^J^^ "^^^^�- ^^^^^^� 
trans- li?,27?-DACH trans-15',25'-DACH cis-1 足 2<S-D ACH 
Figure 3.6.1.2.2.1: The three Isomers of DACH Ligands 
The anti-tumor effect of Pt-DACH compounds was shown to be dependent on the 
absolute configuration of the DACH ligand. Their effectiveness in descending order is: 
[3.13，3.15] 
cw-DACH < trans-S^S-T^kCR < trans-R,R-DACll 
Consistent with the above order of effectiveness, the Pt-DACH drugs, the 
Pt-(c/5-DACH) compounds, drug(24) and drug(39) show a relatively lower potency 
than their tmns-DACH analogue. In addition, their data points fall into the general 
trend of the non-"/ra«5-DACH" platinum drugs, which indicates the additional 
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"DACH" effect exerted by the Pt-(c/5-DACH) drug is insignificant. Therefore, they 
are grouped as the non-"rra«5-DACH" compounds in the QSAR analysis. 
In the following section, the QSAR analysis for the /ra«5-DACH-Pt drug wi l l be 
grouped into two types according to the potency of their "DACH" effect. The first 
type is the trans-S,^-DACH-Pt drugs and the second type is the trans-R,ACH-Pt 
drugs. 
3.6.1.2.2.1 QSAR Study of the ^ra«5-5,5-DACH Platinum Drugs 
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Figure 3.6.1.2.2.1.1: QSAR Plot for the ?ra«5-S,S-DACH Platinum Drugs 
Figure 3.6.1.2.2.1.1 shows the data points of the tmns-S,S-DACli-?t compounds. The 
data point in pink square ( • ) is the Pt-DMC drug. While there are insufficient 
number of data points to construct a meaningful QSAR, it is observed that across the 
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platinum(IV) [Dmg(30)] to platinum(II) [Drug(26)]，the qualitative trend of the 
QSAR is retained, which shows the empirical applicability of the chemical hardness 
on Pt(rV) trans-S,S-DACU drugs. The additional DMC effect may be observed from 
the small downward deviation from the connecting line between Dmgs(26) and (30), 
however, this may not be regarded as a formal conclusion due to the lack of data. 
3.6.1.2.2.2 QSAR Study of trans-R,R-l>ACU platinum Drugs 
logCGIso) against chemical hardness for trans-R,R-DACE 
platinum compound 
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Figure 3.6.1.2.2.2.1: QSAR Plot for the ？ran5-S,S-DACH Platinum Drugs 
Figure 3.6.1.2.2.2.1 shows the QSAR analysis for the trans-R,R-DACB.-?t drugs. 
Again, the data points in the graph generally fall into a linear trend with a satisfactory 
linear regression coefficient. The data in pink square ( • ) for the Pt-DMC-DACH 
drugs again displace a downward deviation from the best fitted line because of the 
additional DMC activity. The downward deviation from the QSAR best fitted line for 
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Drug(31) suggests that the possibility exists that the trans-R,R-DACE. compounds 
show a different chemical hardness dependence for drugs with bidentate carboxylate 
leaving ligand [Drug(25), (27)-(29)] and chloride leaving ligand [Drug(31)]. Again, 
there are insufficient data available to form a conclusion. I f it is assumed the 
Pt-DACH compounds with bidentate and chloride ligands have the same chemical 
hardness dependence, a linear QSAR relationship based on the chemical hardness for 
the drug is proposed (3.6.1.2.2.2.1): 
log(Gl5o) = (2.0621 X r j ) -8.3544 
where GI50 is in unit of M and rj is in unit of eV 
3.6.1.3 Summary 
A universal QSAR for platinum drugs using biological data available from NCI is 
constructed. The entire set of platinum drugs is divided into three categories 
according to their mechanistic behavior. They are the non-'Vra«5-DACH" platinum 
drugs, the trans-S,S-DACH platinum drugs and the trans-R,R-DACH platinum drugs. 
Except for the trans-S, S-DACH platinum drugs, there are insufficient data to form a 
conclusion, the remain two correlations show the unique applicability of the use of the 
chemical hardness in forming a QSAR for platinum drugs. 
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3.7 QSAR Study of the Important Intermediates Using Chemical Hardness 
It is shown in the above QSAR analysis that the drug activity as manifested through 
log(Gl5o) does depend on the chemical hardness and hence the chemical reactivity of 
the compounds. However, it is believed that before the platinum compounds react 
with its ultimate target DNA, it may convert to different reaction intermediates 
according to the DNA binding pathways involved. 
As stated in Chapter one, there are two proposed mechanisms for DNA binding of 
platinum drugs. They are the hydrolysis pathway and the methionine pathway. It 
would be interesting to know i f the log(Gl5o) of the drugs depends on the chemical 
reactivity of the biological intermediate involved. Since it is reasonable to assume that 
the overall biological activity of the drug would depend more critically on the "actual 
active" intermediates than the corresponding parent drugs. Therefore, the chemical 
hardness of the intermediates involved may be used to construct a more reliable 
QSAR. 
In the following section, a comparison of the QSAR constructed by the chemical 
hardness of parent compounds, hydrolysis intermediate and cyclic-methionine 
intermediates is performed. 
The intermediates chosen for the QSAR calculation were: 
a.) For the hydrolysis pathway, intermediate structure is given in (Figure 3.7.1): 
_ k o h J + 
L CI 
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b.) For the methionine pathway, intermediate structure is given in (Figure 3.7.2): 
|— —I + 
CH-
\ 3 
/ P I ) 
L N H - < 
A CO2H 
•• I 
where L is the carrier ligands 
They are the active intermediates that would react with the first guanine according to 
each proposed pathway. The reason for choosing these intermediates is to focus on 
examining the importance of reactivity of the intermediates in the DNA binding step 
on the overall biological activities of the drugs. 
Twelve platinum(II) drugs typically with dichloride leaving ligands were selected for 
this study. They are Drug(l) to (8) and Drug(15) to (18). 
The chemical structures of the intermediates are the same as that shown above (Figure 
3.7.1 and 3.7.2) with L replaced by the corresponding carrier ligands for each drug. 
Table 3.7.1 and 3.7.2 tabulates the results of chemical hardness and the corresponding 
energies of HOMO and LUMO for the hydrolysis and cyclic-methionine 
intermediates respectively. 
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3.7.1 Optimized Structure for the Intermediates 
Intermediates for hydrolysis pathway: 
Dmg( l ) Drug (2) 
f J 
Drug (3) Drug (3，） 
Drug (4) Drug (5) 
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Drug (6) Drug (7) A ^： 
Drug (8) Drug (15) 
V V V 
1 ^ 。 6 — % 
Drug (16) Drug (17) Drug (18) 
Figure 3.7.1.1: Optimized Structures of Hydrolysis Intermediates 
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Intermediates for methionine pathway: 
Drug( l ) Drug (2) 
¥ \ 
Drug (3) o Drug (3，） 
Drug (4) Drug (5) 
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b o 
Drug (6) Drug (7) 
n t 
Drug (8) Drug (15) 
Y § % 
Drug (16) Drug (17) Drug (8) 
H 〇 C 參 N 參 C I 參 P t 參 Q 參 S i 〇 S 〇 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.7.2 QSAR of the Dichloride Pt-Drugs Using Chemical Hardness of Parent 
Compounds 
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Figure 3.7.2.1 ： QSAR plot for the Pt-dichloride drugs with chemical hardness of parent compounds 
Figure 3.7.2.1 shows the QSAR plot for the parent compounds of the dichloride 
platinum(II) drugs. As described before, except for the Drug(17) and (18)，the data 
points forms a linear trend. 
As mentioned before, the logCGIso) do not solely depend on the chemical hardness, 
thus small deviation from the trend is expected. For a smaller data set (only twelve 
dichloride platinum(II) c o m p o u n d s ) , a small deviation in the plot would result in a 
relatively large decline in the overall quality of the linearity. 
To meaningfully compare between the QSAR of the parents drugs with the two 
biological intermediates, the data points with chemical structure which is obviously 
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different from others should be avoided. When the detail structure of Drug(2) is 
investigated, it is found that this drug has the electronegative hydroxide group 
attached to the N atom in the carrier ligands coordinating to the platinum center. 
This is different from other drugs in the plot which have the electropositive carbon 
or hydrogen attached to this corresponding N atom. This leads to the small deviation 
for Drug(2) from the trend line, hence it is removed from the QSAR comparison. 
For similar reason discussed in the last section, the points for Dmg(17) and (18) are 
also excluded in forming the trend line. 
3.7.3 QSAR of the Dichloride Pt-Drugs Using Chemical Hardness of Hydrolysis 
Intermediates 
log(Gl5o) against chemical hardness (hydrolysis 
intermediates) 
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Figure 3.7.3.1: QSAR Plot for the Hydrolysis Intermediates of Pt-dichloride Drugs with 
Chemical Hardness 
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The QSAR plot of log(Gl5o) against the chemical hardness of the hydrolysis 
intermediates for the twelve platinum(II) dichloride drugs shows no correlation as 
demonstrated by the plot in figure 3.7.3.1. Note that the points for (3) and (3，） 
denotes the H2O molecule substituted to the position trans to the ligand 
4-methoxyphenethylamine and ammine respectively. 
A quick inspection confirms that there is little linearity observed for this set of data 
points, the line regression coefficient (black line) obtained is unsatisfactory when 
compared with the QSAR of their parent compounds. From the spread of the values 
obtained for the data, the data points of Drug(3), (3') and Drug(8) that have 
4-methoxyphenethylamine carrier ligand is separated from the other data in the plot. 
A similar spread can be found in the QSAR plot of parent compounds. However, in 
the QSAR plot of hydrolysis intermediate, the linear trend obtained for this data set 
with pink square (blue line) shows great difference from the linear regression trend 
line of the overall data set (black line). Therefore, when comparing the QSAR of the 
parent compounds, this QSAR shows a relatively weak universal applicability. 
Moreover, the order of chemical hardness obtained from the hydrolysis 
intermediates does not follow their corresponding parent drugs. For instance, the 
chemical hardness of Drug(3) has a higher chemical hardness than Drug(8) in the 
parent compounds, however, the reverse order is observed for their hydrolysis 
intermediates. This shows that the order of the chemical reactivity of the drugs may 
change upon conversion to their corresponding intermediates. 
To summarize, the quality of the linearity and the universal applicability of the 
QSAR constructed with the hydrolysis intermediates is impaired when compared to 
the QSAR plot of the parent compounds. The may indicate the possible existence of 
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important steps which affects the overall log(Gl5o) value prior to the formation of the 
respective intermediates. 
3.7.4 QSAR of the Dichloride Pt-Drugs Using Chemical Hardness of 
Cyclic-Methionine Intermediates 
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Figure 3.7.4.1: QSAR Plot for the Pt-dichloride Drugs with Chemical Hardness of 
Cyclic-methionine intermediates 
Figure 3.7.4.1 shows the graph of log(Gl5o) against the chemical hardness of the 
cyclic-methionine intermediates for the twelve platinum(II) dichloride drugs. Again 
data points belonging to Drug(2), (17) and (18) are eliminated. In addition, the data 
point for Drug (16) is missing because the PCM calculation for this molecule cannot 
be converged in Gaussian 98. Drug (3) and Drug (3，) represent the S-atom in 
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methionine molecule attached to the position trans to the ligand 
4-methoxyphenethylamine and ammine respectively. 
The general chemical hardness of this cyclic-methionine intermediate is found to be 
lower than the parent compounds. It is reasonable to expect the reaction 
intermediates to have higher chemical reactivity than their parent compounds. 
Similar to the QSAR plot presented for the hydrolysis intermediate, this plot 
generally reproduce the qualitative trend of the QSAR plot of their parent 
compounds. However, the linearly is unsatisfactory quantitative work because of the 
low linear regression coefficient. 
Intermediate (3) and (3') posses significantly different chemical hardness showing 
that the substitution position of the methionine plays an important role in the 
chemical reactivity of the molecule. 
Similar to the hydrolysis intermediates plot, some changes in the order of chemical 
hardness from the parent QSAR plot exists. 
And, similar conclusion for the hydrolysis intermediates QSAR plot can be drawn 
for this QSAR analysis. 
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3.7.5 Conclusion 
Since QSAR plots of the hydrolysis and cyclic-methionine intermediates cannot 
produce a satisfactory prediction of the log(Gl5o) of the drugs, it is concluded there 
may exist some important reaction steps that can affect the overall log(Gl5o) before 
the formation of the intermediates. In addition, the strong correlation between the 
log(Gl5o) and the chemical hardness of the parent drugs indicated that biological 
reaction involving the parent drugs are important. In order to study the details of 
chemical reactivity of parent compounds, the thermodynamics and kinetics 
information for the first step of the reaction scheme in each possible DNA binding 
pathway are investigated. 
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Chapter Four 
QSAR Analysis for Platinum Drugs Using Specific Reaction Energy Parameters 
4.1 Introduction 
In Chapter 3，a comparison were made for QSAR plots constructed using the chemical 
hardness of the parent platinum(II) drugs with dichloride ligands, their hydrolysis 
intermediates and cyclic-methionine intermediates. The results suggests that there 
may plausible exists important reaction steps that can affect the overall log(Gl5o) 
before the formation of the biological intermediates. Consequently the reactivities of 
the parent drugs is expected to play a primary role in determining the log(Gl5o) of the 
drug. In this chapter, the chemical reactivities of the parent drugs wil l be further 
studied. Specifically, the thermodynamics and kinetics of the first reaction step in 
each possible biological pathway (direct guanine binding pathway, hydrolysis 
pathway and methionine pathway) will be studied in details. 
Objectives: 
The objectives of this part of the study are: 
1.) To construct a more reliable QSAR using the specific energy profile parameters 
that platinum drugs encountered in the biological system, and to provide a QSAR 
with a clear physical meaning which may be suitable for drug design. 
2.) To obtain mechanistic information for Pt-DNA binding through the QSARs 
constructed. 
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4.2 Study Scheme 
Direct Guanine Binding Pathway: 
O 
k .CI 「L\ n "1 
(A) > t + 《 T nh ^ , t \ o + c r 
L CI N - ^ N ^ N H , L 《 N Y ^ N H 
Hydrolysis Pathway: 
L\ ,CI 「 k .CI "1 + 
(B) > t + HP /Pt + C|-
l / CI L OH2 
Methionine Pathway: 
(C) > C + H 广 S — o H ^ 5 " I + Cl-
L CI r U H3C ^ ^ ^ O H 
NH2 
The three reactions outlined above for the twelve platinum(II) drugs with dichloride 
ligands were studied. The thermodynamic and kinetics data for the reaction were 
obtained according to the reaction scheme stated in Chapter two. 
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4.3 Optimized Structures: 
Figure 4.3.1 shows the optimized structure for the three attacking nucleophilies for the 




Figure 4.3.2 illustrates the geometry transform action of the platinum complexes in 
the Reaction (A), (B) and (C). 
Reactant 
Reaction A Reaction B Reaction C 
TS - reaction A TS - reaction B TS - reaction C 
Product - reaction A Product 一 reaction B Product — reaction C 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.4 Comments on the Reliability of the Calculation Model 
Tables 4-1, 4-2 and 4-3 summarize the thermodynamics and kinetics results of the 
three reactions for gas phase, solution phase (with simple solvation model employed) 
and solution phase (PCM solvation model using UAHF atomic radii) respectively. 
Although there is a lack of experimental data available for a thorough judgment on the 
accuracy of the calculation model, it remains possible to provide a qualitative 
judgment regarding the quality of the calculation. 
Experimental data available for the calculation: 
Reaction B for cisplatin: AG(hydrolysis) = 24.2 [々 .！]，23.0 kJmor^ [4 2] 
AG+(hydrolysis) = 100.3，97.5, 98.8，99.9 [《 ]^ and 
99.4 [4.2】kJmori 
Reaction C for cisplatin: AG+(methionine) = 84.4 [4 3]kJmor丨 and rapid [《斗] 
Hydration solvation energy for chloride ion at 25。C =-313.8 [4.5] kJmol-i 
Hydration solvation energy for water molecule at 25°C =-18.4 [4 5]kJmori 
The Comparison of the calculation results with the available experimental results is 
summarized in the Table 4-5 in page 121 in this thesis. Reader can refer to this table 
for the details of the comparison. 
103 
4.4.1 Reaction Profile in the Gas Phase 
Reaction energy results from the gas phase convincingly show the importance of the 
incorporation of solvation effect in the calculation. Without the incorporation of the 
solvation effect, all the values obtained for the free energy (AG) are much more 
positive than the activation energy (AG+) of the corresponding reaction. 
Reaction Profile for the Gas Phase Reaction 







� / incorporation of the 
^ / 
I transition s t a t ^ solvation effect 
y / \ products in solution phase 
reactants 
reaction coordinate 
Figure 4.4.1.1: Energy Profile for the Gas Phase Reaction. 
In Figure 4.4.1.1, the blue line indicates the relative energy for the reaction products 
in the gas phase. The highly unfavorable thermodynamics profile results are attributed 
mainly to the formation of the charged product species, the chloride and the platinum 
complex ions. In the gas phase, the formal charge of the product ions cannot gain 
stability from interaction with the solvent (water) molecules. Experimentally, 
hydration of chloride ions provides additional solvation stability of -313.8 kJmor^. 
This accounts for most of the source of the highly unfavorable thermodynamics 
results for the three reactions. 
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With the available experimental values for cisplatin [Drug(6)], the deviation 
concerning the AG(hydrolysis) is about +507.71 klmol"^ which is 〜11 times the 
experimental value. This confirms the importance of the solvation effect in the 
reliability of thermodynamics results for the above three reaction studied. 
When considering the kinetics results obtained from the gas phase calculation, 
noticeable deviation from experimental results also occurred in the case of cisplatin. 
The deviation for the AG+(hydrolysis) is about 31 kJinol"' lower than the experimental 
results, which corresponds to a relative error of about -32%. The deviation for the 
AG+(methionine) is about 13 kJmor^ lower than the experimental value and the 
corresponding relative error is about -15%. 
Thus, the gas phase model is not an accurate tool to construct the energy profile for 
the three reactions. 
4.4.2 Reaction Profiles Using Simple Solvation Model 
From the results obtained by employing the simple solvation model in Patrick's earlier 
work, [4.6] reaction (A), (B) and (C) of cisplatin are well mimic and with reliable 
accuracy. The AG(hydrolysis) calculated using this model is 34.98 kJmor\ while 
the corresponding experimental result is 23.0 - 24.2 kJmor'. This shows significant 
improvement when compare with gas phase results. 
The AG+(hydrolysis) obtained using this simple model is 112.68 kJmol"' with the 
corresponding experimental values being in the range of 97.5- 100.3 kJmorV This 
indicates both the thermodynamics and kinetics aspect of the cisplatin hydrolysis can 
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be reasonable reproduced by this calculation method. 
Based on the calculation results, the relative magnitude of the activation energy for 
the three reactions in ascending order is: 
AG+(methionine) < AG+(hydrolysis) < AG+(g uanine) 
This order matches experimental observation qualitatively. Although the 
AG+(methionine) seems to deviate from the experimental value by about 73.4 kJmol"^， 
the experimental value was obtained using the HPLC technique [4.3]. Query is raised 
by Eding et al [4.7] on the reliability of the results due to the fact that HPLC is a 
relatively slow detection technique. Nevertheless, it is no doubt that the cisplatin 
reacts with methionine in a much faster rate than that with water. This is demonstrated 
by the experimental results reported by Sadler et al. that the first detected species of 
the reaction between cisplatin and methionine was [Pt(NH3)2(Met-S，N)]+ rather than 
the hydrolysis intermediate [Pt(NH3)2(H20)Cl]+. [4.8] 
On the other hand, there is no experimental value available for the AG+(guanine)， 
since in the ordinary condition, cisplatin would react with the water prior to the 
reaction with guanine or DNA. Therefore, no direct attack of the guanine or DNA was 
observed to construct the energy profile of reaction (A). However, calculation results 
of the relative order of AG+(hydrolysis) < AG+(guanine) do match the experimental 
observation that guanine reacts with cisplatin in a much slower rate than that of water 
and the hydrolysis reaction rather than the direct guanine or DNA binding are 
observed [1.38，1.39]. 
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4.4.2.1 Defects of The Simple Solvation Model 
Despite the successful application of the calculation model on the three first step 
reaction of cisplatin, the reliability of the model seems unable to be extended to other 
platinum drugs studied. 
The energy range obtained for the reaction (A) and (C) is extraordinarily large; 
AG(guanine): (-233.08 kJmol"' to 33.19 kJmol''), AG+(guanine): (-167.89 kJmor' to 
196.16 kJmol"'), AG(methionine): (-207.92 klmol"' to 34.92 kJmor^), 
AG+(methionine): (-255.17 kJmol"^ to 69.35 kJmol'^). 
This extraordinary wide range can be illustrated by breaking the solvation energy into 
its constituting components. Table 4-4 shows the relative values of each component of 
this simple solvation model. Recall that the three contributions for the solvation 
energy are 1.) electrostatic interaction between solvent and solute [AG(eiectrostatic)], 2.) 
dispersive-repulsive interaction encounter for the induced-dipole-induce-dipole 
interaction [G(disp-rep)] and 3.) cavitation energy represents the energy required to 
create the cavities for the solute molecules [G(cavity)]. From the results in table 4-4, it 
is found that the cavitation energy is the main contribution to the overall solvation 
energy except for water molecule and chloride ion. In neutral molecules, the 
reactants and the transition state, cavitation energy contributes about hundred to few 
hundreds kJmol'^ to the solvation energy (except water), while the 
dispersive-repulsive and electrostatic interaction contribute a few kJmol"^ and a few 
tenths ofkJmol"' respectively. In the charged species, chloride ions and other platinum 
reaction products, cavitation energy contribute in an order of magnitude similar to that 
found for neutral species. While the portion of the electrostatic interaction increase 
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significantly (few tenths to hundred klmol"' for platinum products and 379 kJmol'^ for 
Cr ion) and the dispersive-repulsive interaction remains at a few kJmor^. 
Actually, the origin for responsible of the wide energy range obtained in the 
calculation is mainly attributed to the oversimplified definition of the solute-solvent 
boundary for this solvation model. It is no doubt that the "cavitation energy" 
component plays a determining role in the accuracy of the overall solvation energy in 
this solvation model. 
The employed cavitation term obtained from the particle theory assumes the solute 
molecules as the perfect sphere cavity. [2.18] For small molecules, such as cisplatin, 
this assumption can be accepted and satisfactory calculation can be obtained. 
However, as the molecular size increases, especially, for reaction (A) and (C), which 
involve the guanine and methionine attaching to the platinum drugs, the molecular 
shape cannot be approximated by perfect sphere. This results in an unrealistic energy 
spread for these two reactions. 
Reaction (B) that involves relative small size molecules seems to produce more 
reasonable results. At the same time, same defect found in reaction (A) and (C) is 
observed for the largest member in the series, Drug (8)，this molecule possesses two 
4-methoxyphenethylamine carrier ligands. The AG+(hydrolysis) of Drug (8) is -47 
kJmor\ which shows great difference from the corresponding values for other drugs 
studied. Clearly, the spherical cavity assumption cannot be applied universally to 
estimate the important solvation energy for platinum drug reactions. 
Therefore, another solvation model (PCM-UAHF) was tested for its validity in the 
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construction of a more realistic energy profile for the three reactions. 
4.4.3 Reaction Profile using PCM-UAHF Solvation Model 
The last column in Table 4.4 indicates the solvation energy obtained by the PCM 
model calculation. PCM models provide the more realistic definition of the molecular 




View from the side View from the top 
Figure 4.4.3.1) Schematic Diagram of the Molecular Cavity of Cisplatin Generated by PCM Model. 
The calculated values of the solvation energy for water and chloride ion is -32.6 
kJmor^ and -329.3 kJinol"' respectively, while the corresponding experimental values 
are -18.4 kJmor^ and -313.8 kJinol"^ respectively. The values obtained for chloride ion 
is satisfactory, while the value obtained for water molecule shows noticeable 
deviation. 
Nevertheless, it is more meaningful to judge the reliability of a solvation model by the 
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relative solvation energy in a reaction rather than their absolute values. Table 4-3 
shows the thermodynamic and kinetic results for reactions (A), (B) and (C) with the 
PCM-UAHF model. The value of AG+(hydrolysis) for cisplatin obtained is 108.82 
kJmol"', which is very close to the experimental values of 97.5 - 100.3 kJmorV While, 
the AG(hydrolysis) obtained is 39.55 kJmor^ which deviates from the experimental 
value of ~ 24 kJmol"', but is significantly better than the value obtained from the gas 
phase calculation. 
In order to illustrate the general applicability of the PCM-UAHF model for the 
platinum reaction, the hydrolysis of drug JM118 and carboplatin were studied by the 
same methodology. 
O 
H3N CI V - 0 /NH3 
/ - A X o tK 
< > 皿 2 CI NH3 
JM118 Carboplatin 
JM118 (c/5-amminedichlorocyclohexylamineplatinum(II)) is the reduced form of the 
third generation platinum(IV) anti-cancer drug JM216 
(c/5,d5,/ra«5-Pt(NH3)(c-C6HiiNH2)Cl2(OOCCH3)2). 
The hydrolysis reaction of JM118 was studied in details by Zhu et al [4.9] 
theoretically. Solvation effects encountered in the hydrolysis reaction was studied in 
depth by employing both the explicit and implicit solvent model in their calculation, 
and the validity of their model was tested against the parent cisplatin drug. Also, their 
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result indicated a relatively slow aquation rate of JM118 (AG+(hydrolysis) = 107.5 
kJmol'') when compare with cisplatin (AG+(hydrolysis) = 95.8 klmol"') matching the 
proposed underlying reason of the axial steric hindrance caused by the cyclohexyl 
ring. 
It is encouraging that similar results can be obtained in this work using the 
PCM-UAHF model. The AG+(hydrolysis) obtained for JM118 in this study is 112.1 
kJmori which is close to the value of 107.5 klmol"' reported by Zhu et al and a faster 
aquation rate was also obtained for cisplatin (AG+(hydrolysis) = 108.8 kJinol"'). For 
the thermodynamics aspect, the results obtained by Zhu et a. I and from this work 
showed the hydrolysis of JM118 being endothermic. (AG(hydrolysis) by Zhu et al = 
27.6 kJmori and AG(hydrolysis) in this work = 43.8 kJmol"'). 
For carboplatin, it is well known that hydrolysis is extremely slow. The relative 
inertness of carboplatin to hydrolysis was illustrated by Cleare al. in earlier on 
publications [4.10, 4.11]. Subsequently Knox et al. reported a rate of hydrolysis of 7.2 
X 10-7 s'丨(AG+(hydrolysis) = 123 kJmol"') in phosphate bufTer at 310 K [4.12]. Other 
workers such as Canoves et al. [4.13] and Sadler et al [1.40] suggested the rate 
constant o f the hydrolysis should be less than 10"® s"' and 5 x I c r V ' respectively. In 
this study the AG+(hydrolysis) obtained for carboplatin is 125.5 klmol"' which is 
larger than the corresponding value of cisplatin by about 17 kJmol"'. This matches the 
observation for the relative inertness of the carboplatin to hydrolysis reaction. 
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4.4.3.1 Selection of the Reaction Parameters for the QSAR Study 
Although the qualitative reliability of the calculation using PCM model was shown 
for the hydrolysis reaction, the lack of experimental data for reaction (A) forbids one 
to comment on the reliability of the results in reaction (A). As mentioned before, for 
the case of cisplatin, the rate for hydrolysis is much faster than the direct attack of 
guanine or DNA. It may be assumed that similar circumstances occur in other 
platinum drugs studied they possess the dichloride leaving ligands. Obviously, 
calculation results show that for each platinum drug studied, the AG+(guanine) is 
higher than AG+(hydrolysis) consistent with the assumption made. Hence, it is worth 
to employ the calculated results of reaction (A) in constructing the QSAR of the 
platinum drug. 
For reaction (C)，the calculated data fails to reproduce the qualitative trend observed, 
AG+(methionine) < AG+(hydrolysis)，for cisplatin. Similarly it consistently predicts a 
large value for AG+(methionine) for each of the drugs studied when compared with 
their corresponding AG+(hydrolysis). This off sets the logical expectation that 
platinum drugs reacts in a faster rate with methionine than water. Thus, the data for 
reaction (C) would not be used for constructing the QSAR for the platinum drug in 
this work. In short, only qualitatively reliable results from reactions(A) and (B) wi l l 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.5 QSAR Study of Platinum Drugs using the Reaction Parameters (AG and 
AG+) 
In the following section, the QSAR plot for dichloride platinum drugs wil l be 
constructed using AG+(hydrolysis), AG(hydrolysis), AG+(guanine) and AG(guanine). 
Similar to the QSAR plot constructed for the possible biological intermediates in the 
last Chapter, Drug (2), (17) and (18) wil l be excluded from the analysis. 
4.5.1 QSAR Analysis using AG+(hydrolysis) 
log(Gl5o) against 八 G+(hydrolysis) of the Pt-dichloride Drug 
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Figure 4.5.1.1 QSAR plot of the Pt-Dichloride Drugs Using AG+(hydro lysis) 
Figure 4.5.1.1 shows the QSAR plot constructed using the log(Gl5o) and the activation 
energy of the hydrolysis, AG+(hydrolysis), for the dichloride compounds. Among the 
drug candidates, the rate of cisplatin [Drug (6)], which involves the least steric carrier 
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ligands, has the highest rate of hydrolysis. However, there is no clear relationship 
between the steric factor and the rate of hydrolysis. 
As shown in the plot, although qualitative correlations between AG+(hydrolysis) and 
potency is obtained, the correlation is not strong 0.6081)，Drug(l) and Dmg(8) 
deviate significantly from the trend. The point (3) and (3，）denotes the nucleophilic 
substitution by water in position trans to the 4-methoxyphenethylamine and amine 
carrier ligands respectively. In this graph, the point (3，）with a higher AG+(hydrolysis) 
is excluded from the trend line consideration to avoid double counting of the effect of 
Drug(3). 
Recall the conclusion made in Chapter Three, it is believed that the reaction profile 
for the first step of the biological pathway of platinum drugs plays an essential role in 
determining the overall biological activity of the drugs. Therefore, it is expected that 
a satisfactory linear relationship between the log(Gl5o) and the AG+(hydrolysis) (the 
potency increase as activation energy decrease) could be obtained. However, this was 
not found in the QSAR analysis, and several explanations are proposed to understand 
the observed scenario: 
1.) Hydrolysis is not a dominating biological pathway for the platinum drugs. It was 
expected that cisplain and other platinum drugs react with the sulfur-containing 
bio-molecules in a much faster rate than water molecules. The "Drug reservoir" 
concept confirmed that the Pt-S interaction could mediate the Pt-DNA binding. I f 
this is the case, the rate of hydrolysis would expect to play a less significant role 
in determining the overall potency of the drugs than the corresponding rate of 
methionine binding reaction. However, the reliability of the calculated energy 
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profile for the methionine binding in this work prevents us to carry out further 
QSAR analysis for the methionine pathway. 
2.) Narrow energy range for the AG+(hydrolysis) limits one to differentiate the 
potency of the drugs by the rate of hydrolysis theoretically. The range of 
AG+(hydrolysis) is between 108.82 kJmol"' for Drug (6) and 119.02 kJmor' for 
Drug (15) and there is only about 10 kJmor' difference. Unless the experimental 
values of the rate of hydrolysis for each drug is known, it is difficult to ensure the 
theoretical values of AG+(hydrolysis) obtained for the drugs match exactly the 
trends of the corresponding data obtained from experiments. In this sense, it is not 
advisable to construct a QSAR plot using theoretically estimated values of 
AG+(hydrolysis). 
4.5.2 QSAR Analysis using AG(hydrolysis) 
logCGIso) against A G(hydrolysis) of the Pt-Dichloride Drug 
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Figure 4.5.2.1 QSAR plot of the Pt-Dichloride Drugs Using AG(hydrolysis) 
123 
Figure 4.5.2.1 shows the QSAR plot constructed by the AG(hydrolysis). A l l the 
hydrolysis reactions for the drugs are endothermic as in the case of cisplatin. 
In the case of Drug(3), reaction(3) that involves the substitution of water trans to the 
4-methoxyphenethylamine carrier ligand is found to be a more favorable reaction. 
This indicates water molecules prefer to bind to the platinum center trans to 
4-methoxyphenethylamine carrier ligand both kinetically and thermodynamically. 
Regarding the energy range obtained from the calculation, AG(hydrolysis) is even 
narrower than the corresponding AG+(hydrolysis) plot with only 〜6 kJmol"' energy 
difference (Smallest: Drug (4) with 38.49 kJmol] and Largest: Drug (7) with 44.15 
kJmor'). This implies that thermodynamics properties of the drugs towards hydrolysis 
are similar. 
Concerning the relationship between the two parameters [AG(hydrolysis) and 
log(Gl5o)], no obviously correlation is observed. It is believed that reasons for the 
failure to construct a useful QSAR plot using the free energy of hydrolysis is similar 
to the proposed explanation for the AG+(hydrolysis). 
In conclusion, by the two QSAR plot shown, the overall potency of the dichloride 
platinum drugs do not have a quantitative reliable correlation with the 
thermodynamics and kinetics properties of the first reaction step in the hydrolysis 
reactions. The first reason may be due to the relatively insignificant role of the 
hydrolysis pathway when compared with the more rapid methionine pathway. The 
second reason may due to failure of the calculation model to reproduce the qualitative 
reactivity trend among the platinum drugs towards the hydrolysis because both the 
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AG^(hydrolysis) and AG(hydrolysis) are confined within a small energy range. 
Therefore, there is no QSAR with AG+(hydrolysis) and AG(hydrolysis) can be 
constructed . 
4.5.3 QSAR Analysis using AG+(guaiime) 
logCGIso) against AG^(guanine) of the Pt-Dichloride Drug 
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Figure 4.5.3.1 QSAR plot of the Pt-Dichloride Drugs Using AG+(guanine) 
Figure 4.5.3.1 shows the correlation between logCGIso) and AG+(guanine). Similar to 
the AG+(hydrolysis) QSAR plot, a qualitative trend (constructed by the blue points) 
with a significant deviation point of the largest molecules, Drug (8) (pink square) (•)， 
is observed. For the guanine binding of Dmg(3), reaction(3') that has a higher 
activation energy is excluded from the consideration of the linear trend. This avoids 
the effect of drug(3) being double counted in the trend line. 
It is generally believed that the direct guanine binding reaction is not a major DNA 
125 
binding pathway. Instead，water and the sulfur-containing biomolecules react in a 
much rapid rate with platinum drugs. Hence, it is expected that AG+(guanine) should 
play an insignificant role in determining the overall potency of the drugs. 
However, the qualitative trend obtained in Figure 4.5.3.1 shows that the contribution 
of the direct guanine attack pathway is significant on the overall potency of the drugs. 
The linear regression coefficient obtained in this plot is R^=0.6544 which is similar to 
R2=0.6081 obtained by the AG+(hydrolysis) plot, and the large deviated point 
[Drug(l)] in AG+(hydrolysis) plot fall within the general linear trend in this 
AG+(guanine) QSAR plot. This suggests the possibility that direct guanine attack 
cannot be ruled out. 
This conclusion tends to misalign with the basic understanding of the platinum drugs 
chemistry. In fact, the reason of this contradiction may be due to the sources of 
information for the cisplatin DNA binding. Actually, it is worth to mention that all 
kinetics information obtained for the cisplatin DNA binding came from the 
experiments conducted with isolated guanine or DNA. The information obtained from 
the simplified isolated experiments may not be applicable on the complicated cell 
environment. Therefore, the possibility of the direct DNA binding pathway cannot be 
neglected. 
From the correlation trend of the log(Gl5o) and AG+(guanine)，it is observed that as 
the activation energy of the guanine binding decrease, the potency of the drugs 
increase. This is consistent with the basic expectation for platinum drugs i f the 
possibility of DNA direct binding is not neglected. 
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4.5.4 QSAR Analysis using AG(guanine) 
logCGIso) against AG(guanine) of the Pt-Dichloride Drug 
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Figure 4.5.4.1 QSAR plot of the Pt-Dichloride Drugs Using AG+(guanine) 
Figure 4.5.4.1 shows the QSAR plot constructed using AG(guanine). The parameter 
AG(guanine) denotes the thermodynamics properties of the Pt-Guanine or Pt-DNA 
binding. Since the free energy change of a reaction is a state function that is 
independent of the reaction pathways, AG(guanine) provides a valuable information 
for the relative DNA binding affinity of the dichloride platinum drugs. 
While DNA is the ultimate biological target for the platinum drugs to induce the 
cytotoxic effect on the tumor cell, the AG(guanine) which measures the DNA binding 
affinity plays very important role in the overall potency of the drugs. 
The strong correlation obtained in the main trend line demonstrates the rationale 
proposed above, that is the potency of the drug increases as the DNA binding affinity 
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increases. 
Again, the data point for Drug (8) significantly deviates from the trend line. The 
possible explanation may be due to the accuracy of the calculation model on this large 
molecule, the two large 4-methoxyphenethylamine ligands prevent the calculation 
model to obtain a reliable result on the AG(guanine). In addition, only the data point 
of (3) is taken into consideration in forming the linear plot. The point (3，）which 
shows smaller Pt-Guanine affinity and lower rate of nucleophilic substitution is not 
included to prevent double counting of the effect of Dmg(3). 
Therefore, the QSAR plot constructed using the AG(guanine) provides another useful 
and reliable tool in the rational design of platinum drugs tool. With clear physical 
meaning provided by this QSAR, researchers may focus the design of drug with large 
Pt-DNA binding affinity. Based on the theoretical calculation obtained in this study, 
the Pt-DNA binding affinity of the drugs can be obtained. In addition, using the 
semi-quantitative QSAR relationships obtained in this work, the approximate potency 
of a drug can be obtained: 
log(Gl5o) = [0.0126 X AG(guanine)] - 4.7259 
where GI50 is in unit of M，AG(guanine) is in unit ofklmol'^ 
To conclude, the values of log(Gl5o) are found to be related with the reaction energy 
parameters of the guanine binding reaction, AG+(guanine) and AG(guanine). This 
indicates the importance of the guanine or DNA binding affinity in platinum drug 
design. Also, with the suggested linear equation between log(Gl5o) and AG(guanine), 
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researchers may find a useful application of the theoretical calculation in this work. 
4.5.5 Further Investigation of the Bidentate Pt-drugs DNA Binding 
Results from the last section show the useful application of the reaction parameters 
from the direct guanine binding in constructing the QSAR of the dichloride platinum 
drugs. In this section, a similar QSAR analysis is performed for carboplatin and the 
five Pt-DMC drugs mentioned. The aims of this section are to explore the QSAR 
applicability of AG+(guanine) and AG(guanine) on the platinum drugs with the 
carboxylate bidentate ligands which is another important class of the platinum drugs. 
4.5.5.1Calculation Model 
Unfortunately, the model BP86/LanL2DZ with the solvation model PCM-UAHF 
which is applicable on the direct guanine reaction of the dichloride platinum drugs 
cannot match the experimental results of the six bidentate Pt-drugs. (Table 4-6 and 4-7) 
Therefore, PCM model with other definition of atomic radii were employed: United 
Atom Topological Model (UAO), United Atom Topological Model (UAKS) and radii 
from the UFF force field (UFF). In addition, calculation model mPWlPW91/SDD 
which was shown by Zhang et al [4.14] to have the superior accuracy in predicting 
the geometry of cisplatin from a comprehensive methodological study was employed 
in this work to mimic the reaction between the six bidentate drugs and guanine. 
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4.5.5.2 Bidentate Pt-drugs Reactions 
NH NH3 广 o 
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4.5.5.3 Selection of the Calculated Model for the QSAR Study 
Tables 4-6 and 4-7 show the calculated results AG+(guanine) and AG(guanine) for 
carboplatin and five Pt-DMC compounds using different computational models. It is 
believed that carboplatin [1.40] and Pt-DMC compounds [4.15] that possess the 
carboxylate leaving ligands can undergo direct guanine or DNA binding and have 
relatively high stability towards hydrolysis. This differs from the present knowledge 
obtained from the dichloride Pt-Drugs. Wang et al. [4.15] measured the rate of the 
reaction of the five Pt-DMC drug and carboplatin with the 5'-GMP 
(5'-monophosphate guanosine). Kinetics results showed the order of reaction rate to 
be (Table 4-7): 
carbolplatin < compound 2 < compound 4 < compound 3 < compound 1 < compound 5 
The reliability of different methods is judged by, first, the matching of the above order 
of reaction rate among the compounds and, second, the absolute values deviated from 
the experimental results. From the results of tables 4-6 and 4-7，it is shown that only 
the gas phase model can reasonable predict the qualitative trend of the reaction order. 
Other models with the solvation energy incorporated show disagreement in 
reproducing the trend of the AG十(guanine)，although some models show a relatively 
smaller mean deviation from the experimental results (Table 4-8). This indicates that 
the model with solvation effect employed may not suit the system of platinum 
compounds with carboxylates bidentate ligands. On the other hands, simple gas phase 
calculation is worthy of a qualitative description of the reaction between bidentate 
Pt-drugs with guanine. In addition, since the reaction products of the first nucleophilic 
substitution of the bidentate Pt-drugs are neutral in charge (one head of the bidentate 
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ligands still attaching to the platinum), the defects of gas model in predicting the 
energy of charge species can be avoided. Therefore, both the AG+(guanine) and 
AG(guanine) obtained from the gas phase model were employed to construct the 
QSAR of the six bidentate Pt-drugs in this work. 
For the two gas phase calculation model, although the deviation obtained from the 
model mPlPW91/SDD (-45.58 kJmol"^) is larger than that of the results obtained from 
the model BP86/LanL2DZ (-29.66 kJmol'') (Table 4-8)，the qualitative trend of the 
former match exactly with the experimental results. While for the BP86/LanL2DZ, 
the data point of compound 3 is larger than the expected trend. Therefore, the reaction 
energy obtained from the model mPlPW91/SDD will be used to construct the QSAR 







































































































































































































































































































































































































4.5.5.4 QSAR Analysis using AG+(guaiime) for the Platinum Drugs with 
Bidentate Carboxylate Ligands: 
log (GI50) against the AG+(guanine) of the Pt-bidentate drugs 
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Figure 4.5.5.4.1 QSAR plot of the Bidenate Pt-Drugs Using AG+(guanine) 
Figure 4.5.5.4.1 shows the correlation between log(Gl5o) value and AG+(guanine). 
Similar to the dichloride—Pt drugs studied in the last section, qualitative correlation 
between the log(Gl5。）and AG+(guanine) is observed. 
It is believed that carboplatin and the five Pt-DMC drugs undergo direct DNA binding 
rather than the hydrolysis pathway. The finding of this work match well to this 
important DNA binding mechanism with the potency of the drug increases as the rate 
of direct guanine binding increases. 
We have mentioned that both the DMC and trans-R,R-DACR ligands posses the 
additional biological activity which cannot be predicted by the chemical reactivity of 
the drugs. Hence, carboplatin (pink square) without DMC and tmns-R.R-DACR and 
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compound 5 (brown triangle), with both DMC and trans-R,R-DACR are separated 
from the group of compounds 1-4 (blue diamond) which possess ligand DMC, but 
without trans-R,R-DAC}1.. However, the relatively weak correlation between log(Gl5o) 
and AG+(guanine) of compound 1-4，R^ = 0.4351, prevents a semi-quantitative 
prediction of the log(Gl5。）by the AG+(guanine). Therefore the additional DMC and 
trans-R,ACH effects cannot be observed in the QSAR plot. 
4.5.5.5 QSAR Analysis using AG(guanme) for the Platinum Drugs with Bidentate 
Carboxylate Ligands: 
log (GI50) against the AG(guanine) of the Pt-bidentate drug 
caitoplatin 
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Figure 4.5.5.5.1 QSAR plot of the Bidenate Pt-Drugs Using AG(guanine) 
Figure 4.5.5.5.1 shows the correlation between log(Gl5o) value and AG(guanine). A 
stronger correlation is obtained in the QSAR constructed by AG(guanine). The linear 
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trend shows the fact that as the DNA or guanine binding affinity of the drugs increases, 
the potency of the drugs increases. This is consistent with the results obtained for the 
Dichloride-Pt drugs and agrees with the rationale of the platinum drugs chemistry. 
Moreover, the additional DMC and trans-R,R-DACU effects can be observed in this 
QSAR plot. The pink square, carboplatin, which does not have the DMC nor 
trans-R.R-DACU ligands shows an upwards deviation from the trend line constructed 
by the non-'Vra«5-DACH" Pt-DMC drugs, compound 1-4. This indicates the DMC 
effect exerted by compounds 1-4 shifts the trend line downward away from 
carboplatin which possess no DMC effect. On the other hand, compound 5, denoted 
by brown triangle, shows an additional tmns-R,R-DACR effects and deviates from the 
trend line constructed by the non-“/ra似-DACH" Pt-DMC drugs. 
Therefore, the QSAR constructed by AG+(guanine) and AG(guanine) may extend to 
the platinum drugs with bidentate carboxylate leaving ligands. The quality of the 
correlation is better for the QSAR constructed by AG(guanine) and the expected 
additional DMC and trans-R.R-DACH effects is readily observed in the plot. 
4.5.6 Conclusion 
The results in this study carried out on the six bidentate platinum drugs further 
support the applicability of the parameter AG(guanine) in the QSAR study of the 
platinum drugs. The most important criterion for a validated QSAR is to select a 
reliable calculation model to describe the reaction system. In this work, 
BP86/LanL2DZ with PCM-UAHF solvation model was chosen for the platinum drugs 
with dichloride leaving ligand and mPWlPW91 gas phase model was chosen for the 
platinum drugs with the bidentate carboxylate as the leaving ligand. Based on the 
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suggested methodology and QSAR plots, preliminary reference of drug potency can 
be provided before the actual synthetic work is carried out. 
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Chapter Five 
Conclusion Remarks and Future Works 
5.1 Conclusion 
The possibility of using the DFT reactivity parameter, chemical hardness, in 
constructing the practical and universal QSAR for the platinum drugs has been 
explored in this work. Al l the searchable and named platinum drugs with potency data 
available from NCI were selected in the QSAR analysis. The satisfactory correlations 
between chemical hardness and potency found in non-'7ra«5-DACH", 
trans-1ACH platinum drugs demonstrate the usefulness of chemical hardness 
in predicting the potency of the platinum drugs. 
QSAR study using the possible intermediates of the Pt-Cl drugs 一 Hydrolysis 
Intermediates and Cyclic-Methionine Intermediates, results show that potency of the 
drugs depends on the chemical hardness of their parent compounds instead of their 
important possible intermediates. 
Finally, the study of the reaction energy profiles of the first reaction step of the three 
possible DNA binding pathways - direct guanine binding, hydrolysis pathway and 
methionine pathway were investigated for the Pt-Cl drugs. With verification of the 
computed results, AG+(hydrolysis)，AG(hydrolysis), AG+(guanine) and AG(guanine) 
were employed to perform further QSAR analysis. It is found that AG十(guanine) 
shows a noticeable correlation with potency of the drugs, which suggests direct 
guanine binding may exist in complicate cell environment. The strongest correlation 
is found in the QSAR plot of potency against AG(guanine), this suggests that as the 
DNA binding affinity of platinum drugs increase, the potency increases. Linear 
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equation between log(Gl5o) and AG(guanine) are suggested, researchers may find a 
useful reference supported by a clear physical significance in platinum drug design. 
Further QSAR analysis using AG+(guanine) and AG(guanine) are performed for 
platinum drugs with Bidentate Carboxylate leaving ligands. Carboplatin and the five 
Pt-DMC compounds developed in this group were selected for the study, and results 
similar to that obtained for Pt-Cl drugs are observed. 
5.2 Future Works 
The extension to this work can be focused on the empirical calculation of chemical 
hardness. In this study, chemical hardness was calculated by the DFT calculation. 
Although the speed of computational calculation has been increased significantly in 
recent years, the manipulation of computational calculation may not be familiar 
ground to all researchers. Thus, it is worthy to develop an empirical method to obtain 
the value of chemical hardness for the platinum drugs without the actual theoretical 
calculation. Hence, in the future, contribution by different ligand fragments and their 
combined effects to the values of chemical hardness wil l be evaluated. It is hoped that 
with the information obtained by this ligand fragments analysis, a reliable empirical 
method for evaluating chemical hardness can be provided. Our final goal is to obtain a 
model simple enough to be manipulated by only a calculator and hence the QSAR 
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